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Soluble Guanylyl Cyclase (sGC) is responsible for converting GTP to cyclic GMP 
(cGMP). sGC function and regulation is complex and cell-type dependent. An increase in 
cGMP production can target phosphodiesterases (PDEs), cGMP gated ion channels, and 
protein kinase G (PKG). Increasing sGC activity and inhibiting the degradation of cGMP 
by targeting PDEs are two approaches to maintaining cGMP levels in a given system. 
Interestingly, cGMP can also regulate mitochondrial biogenesis (MB), the generation of 
new and functional mitochondria.  
 
Previously in our laboratory, we have shown that MB is suppressed after ischemia and 
reperfusion (I/R) injury and certain mitochondrial biogenic compounds can accelerate 
recovery and attenuate the decrease in MB. In particular, we have shown that 
administration of an inhibitor of PDE5, sildenafil, can restore MB and renal function after 
I/R. However, the role of sGC in I/R is still under investigation. Here, we have elucidated 
a potential signaling pathway for the involvement of sGC in the suppression of MB. We 
performed I/R on mice and focused on the events that occur within the first 24 h of I/R 
injury. We optimized an sGC enzyme assay for the kidney to better understand the redox 
state of sGC. We proposed that the suppression of MB is cGMP-dependent and that PKG 
is a mediator of these effects. Moreover, we have proposed a role for ERK1/2 in the 
sGC/cGMP/PKG induced suppression of MB.  
 
 xiii 
Alternatively, we have shown that cGMP can induce MB in renal proximal tubule cells 
by 24 h with exposure to a cGMP analog, 8-Br-cGMP. However, the mechanism behind 
this finding is unknown.  Therefore, we treated renal proximal tubule cells with a 8-Br-
cGMP, for an 1 h to elucidate the mechanism behind this event. We measured the 
phosphorylation of serine and threonine residues on PGC-1α, the master regulator of MB, 
since phosphorylation can prolong the half-life of PGC-1α and induce MB. We found 
that the induction of MB is PKG dependent and that p38 MAPK plays a prominent role in 
the phosphorylation of PGC-1α.  
 









Chapter 1: Introduction to the Role of Soluble Guanylyl Cyclase Signaling in 


























The kidney is one of the most energy-demanding organs in the human body. A study 
measuring the resting energy expenditure of various organs in healthy adults, ranging 
from 21 to 73 years of age, found that the kidney and heart had the highest resting 
metabolic rates1. The kidney has the second highest mitochondrial content and oxygen 
consumption after the heart2,3. The resting metabolic rate for the kidney is high because 
the kidney requires an abundance of mitochondria to provide sufficient energy to enable 
it to remove waste from the blood, reabsorb nutrients, regulate the balance of electrolytes 
and fluid, maintain acid-base homeostasis, and regulate blood pressure.  
 
Blood is first received from the afferent arteriole and filtered through the glomerulus 
where glucose, ions, urea, and water are able to pass and larger molecules such as 
hemoglobin are retained. Proximal tubules reabsorb 80% of the filtrate that passes 
through the glomerulus, including glucose, ions, and nutrients. These tasks, especially the 
reabsorption of glucose, ions and nutrients through channels and transporters, are driven 
by ion gradients. Filtrate then passes through the loop of Henle consisting of the thin 
descending limb, thin ascending limb, and thick ascending limb. The thin descending 
limb reabsorbs water via passive transport whereas the thin ascending limb is 
impermeable to water reabsorption. Tight junctions in the thin descending limb are 
considered to be more leaky than tight junction in the thin ascending limb. Ion 
reabsorption continues in the thin ascending limb and thick ascending limb however, the 
process in the thick ascending limb requires active transport. Sodium reabsorption occurs 
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in the thick ascending limb through membrane transport proteins, NKCC2, that are 
located on the apical membrane of the thick ascending limb. NKCC2 transport 2 Cl-, 1 
K+, and, 1 Na+ from the urine across the membrane into the thick ascending limb. 
Subsequently, Na+K+ATPases that are located in the basolateral membrane of the thick 
ascending limb, between the bloodstream and thick ascending limb, pump 3 Na+ ions in 
the blood and 2 K+ ions into the thick ascending limb. This allows for the inside of the 
thick ascending limb to be negatively charged and therefore generates an electrochemical 
gradient for proper movement of ions across NKCC2.  Filtrate from the loop of Henle is 
further filtered in the distal convoluted tubule reabsorbing Ca2+, K+, Na+ ions. In order 
to maintain optimum pH, bicarbonate and H+ ions can be reabsorbed or secreted in the 
filtrate. Hormones such as aldosterone and parathyroid hormone (PTH) exhibit their 
effects in the distal convoluted tubule and collecting ducts. Aldosterone can cause the 
reabsorption of Na+ ions and the secretion of K+ ions into the filtrate creating 
downstream effects such as changes in blood pressure, blood volume, and water 
retention. PTH is secreted to cause the retention of Ca2+ in the kidney, bone, and 
intestine. In terms of the kidney, PTH exhibits its effects in the proximal tubule, distal 
convoluted tubule, and collecting ducts. The resulting filtrate is retained in the collecting 
duct until excreted into the renal pelvis. The process of filtration as explained, involves 
active and passive transport mechanisms that allow for the excretion of wastes and 
retention of nutrients, ions, and glucose.  
 
As mentioned above, Na+,K+-ATPases play a large role in the active transport 
mechanisms used to allow for proper filtration of blood in the kidney. Mitochondria 
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provide energy to Na+,K+-ATPase to generate ion gradients across the cellular 
membrane4. In the kidney the proximal tubule, the loop of Henle, the distal tubule and the 
collecting duct all require active transport to reabsorb ions4. This is in contrast to 
glomerular filtration, which is a passive process that is dependent on maintaining 
hydrostatic pressure in the glomeruli. Proximal tubules contain the most ATP-dependent 
ion transporters in the kidney since that reabsorb 80% of the filtrate and as such, they 
contain more mitochondria than any other structure in the kidney. The ability of 
mitochondria to sense and respond to changes in nutrient availability and energy demand 
by maintaining mitochondrial homeostasis is critical to the proper functioning of the 





Mitochondria are a network of plastic organelles that together maintain a variety of 
cellular functions and processes, such as the level of reactive oxygen species, cytosolic 
calcium and apoptosis5. Most importantly, mitochondria produce ATP, thereby supplying 
the energy source for basal cell functions as well as cellular repair and regeneration. To 
accomplish this feat, a population of healthy and functional mitochondria is vital.  
 
[H2] ATP production  
 
Aerobic respiration is the consumption of oxygen to produce ATP, water and carbon 
dioxide. Most of the ATP generated by aerobic respiration is produced by the flux of 
electrons through the electron transport chain (ETC) in a process called oxidative 
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phosphorylation (FIG. 1.1a). Aerobic respiration begins with the production of pyruvate 
from glucose via glycolysis6. Pyruvate is converted to acetyl CoA (via pyruvate 
dehydrogenase in the mitochondrial matrix), which fuels the tricarboxylic acid (TCA) 
cycle to produce six reduced nicotinamide adenine dinucleotide (NADH), four flavin 
adenine dinucleotide (FADH2), and six CO2 per molecule of glucose
6. Electrons from 
NADH and FADH2 are transferred to complex I and complex II, respectively, of the ETC 
in the mitochondrial inner membrane. Electrons travel through the ETC to complex IV, in 
which they are accepted by oxygen. Note that the haemeprotein Cytochrome c, which is 
located in the mitochondrial inner membrane, facilitates the transfer of electrons from 
complex III to complex IV. Ultimately protons, which are actively pumped into the 
intermembrane space as electrons move through complexes I, III, and IV, flow through 





Figure 1.1: ATP production in the kidney 
The electron transport chain (ETC). A functioning ETC transforms reducing equivalents from NADH and 
FADH2 to produce NAD+ and FAD+, respectively. The electrons (e−)that are produced travel through the 
complexes of the ETC and are ultimately accepted by oxygen at complex IV. As electrons are transferred 
from complex to complex, protons (H+) are actively pumped out from complexes I, III, and IV into the 
intermembrane space, maintaining the membrane potential and driving the production of ATP by ATP 
synthase (also known as complex V). b | Fatty acid transport and activation in renal proximal tubule cells. 
Proximal tubules require large amounts of ATP to drive ion transport and therefore rely on aerobic 
respiration, the most efficient mechanism for producing ATP. Fatty acids are a main source of energy for 
proximal tubules because more ATP can be produced from one molecule of palmitate than from one 
molecule of glucose18. Fatty acids bound to fatty acid-binding proteins (FABP) are transported into the 
proximal tubule cell via platelet glycoprotein 4 (also known as CD36) and activated by the addition of 
acetyl-CoA in the cytosol via acyl-CoA synthetase. Activated fatty acids are transported into mitochondria 
via carnitine O-palmitoyltransferase 1 (CPT1), which exchanges their acyl-CoA group for L-carnitine, 
whereupon they undergo β-oxidation to produce ATP. CoQ, coenzyme Q; Cyt C, cytochrome c; MIM, 
mitochondrial inner membrane; MOM, mitochondrial outer membrane; Pi, inorganic phosphate. 
From: Bhargava, P. & Schnellmann, R. G. (2017) Mitochondrial energetics in the kidney 
Nat. Rev. Nephrol. doi:10.1038/nrneph.2017.107 
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In general, all cell types in the kidney need ATP to maintain cellular functions; however, 
the mechanism by which ATP is produced is cell type dependent. For example, in the 
renal cortex, proximal tubules depend on the efficiency of oxidative phosphorylation to 
produce ATP that drives active transport of glucose, ions, and nutrients.7 In contrast, 
glomerular cells including podocytes, endothelial cells, and mesengial cells have lower 
oxidative capacity because their function is to filter blood, removing small molecules 
(glucose, urea, water, and salts) while retaining large proteins such as hemoglobin.8 This 
passive process does not directly require ATP and therefore glomerular cells have the 
ability to perform aerobic and anaerobic respiration to produce ATP for basal cell 
processes.9-12 Anaerobic respiration also begins with glycolysis like aerobic respiration, 
producing pyruvate from glucose, but is characterized by the production of lactate from 
pyruvate13. This is important as cell types other than proximal tubules perform glycolysis 
more often and are able to utilize other energy sources such as amino acids in the absence 
of glucose14,15. For example, pyruvate can be generated via the oxidation of amino acids 
fueling both anaerobic and aerobic mechanisms for ATP production.  
 
Due to the high energy demand of proximal tubules, aerobic respiration is the primary 
mechanism for ATP production. Proximal tubules utilize non-esterified fatty acids, such 
as palmitate, via β-oxidation for maximal ATP production.  A single molecule of 
palmitate produces 106 molecules of ATP whereas the oxidation of glucose only yields 
36 molecules of ATP16,17. Fatty acids are taken up by proximal tubule cells via transport 
proteins, such as platelet glycoprotein 4 (also known as CD36), or synthesized in the 
cytoplasm where they are activated by coenzyme A prior to transport into mitochondria 
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through the carnitine shuttle (FIG. 1.1b)18. Specifically, carnitine O-palmitoyltransferase 
1 (CPT1) exchanges the coenzyme A group on fatty acids with L-carnitine, allowing the 
transfer of fatty acids across the mitochondrial inner membrane space through the 
carnitine shuttle. Fatty acids are then broken down for energy via β-oxidation in the 
mitochondrial matrix. While β-oxidation is the most efficient mechanism for maximal 
ATP production for proximal tubules, it is important to note that due to the high 
consumption of oxygen by proximal tubules, they are more susceptible to changes in 
oxygen levels.19,20 A decrease in oxygen levels can ultimately lead to the impairment of 
β-oxidation and the reduction of ATP production (discussed below). 
 
 
A balance of catabolic and anabolic nutrient sensing pathways regulates the optimal 
concentration of fatty acids in a cell (see below). Disease states and different metabolic 
conditions in the kidney alter this balance and can adversely affect mitochondrial 
energetics. For example, the accumulation of fatty acids in AKI and DN can negatively 
impact ATP production by decreasing β-oxidation in the mitochondria and increasing the 
formation of lipid droplets inside the cell17. An inverse correlation exists between 
lipogenesis that is induced by the accumulation of fatty acids and the transcription of 
genes, the protein products of which are involved in fatty acid oxidation21,22. Fatty acids 
can also trigger apoptosis and more importantly, create a toxic environment inside the 
cell that hinders mitochondrial function23,24. Fatty acid metabolism in disease states such 
as AKI and DN will be discussed below.  
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[H2] Antioxidant Defenses  
 
As discussed, mitochondria produce ATP via the ETC. At steady state, when electrons 
are passed through the ETC to molecular oxygen, - a low concentration of superoxide 
anions are generated from complex I and complex III. Although a low level of reactive 
oxygen species (ROS) such as these is important for cell function, high concentrations are 
toxic to mitochondria and the cell (FIG. 1.2)25-27. For example, under oxidative stress, 
increased levels of ROS can cause breaks in mitochondrial DNA (mtDNA) that cause 
mutations in the next generation of mitochondria, negatively affecting the efficiency of 
the ETC causing a decrease in ATP production, and damage proteins and lipids28. ROS 
can also trigger apoptosis in the cell by causing the release of cytochrome c and leading 
to mitochondrial dysfunction28. Therefore, mitochondria have antioxidant defense 
systems to counteract the excessive formation of additional ROS. Superoxide dismutase 2 
(SOD2), which converts superoxide anions to hydrogen peroxide and oxygen, is specific 
for mitochondria29. Moreover, the transcription of genes encoding antioxidant enzymes 
such as SOD2, catalase, and glutathione peroxidase is activated by nuclear factor 
erythroid 2-related factor 2 (NRF2), in response to oxidative stress, providing a 
mechanism to prevent excessive ROS production 30. The importance of these antioxidant 




Figure 1.2: Oxidative Stress and the Antioxidant Defence System 
Insults can increase the production of reactive oxygen species (ROS) in the cytosol and mitochondria. 
NADPH oxidase 2 (NOX2) and NOX4 can also contribute to the production of ROS222. The production of 
ROS can cause breaks in mitochondrial DNA (mtDNA) and damage lipids and proteins. Damaged mtDNA 
can produce aberrant mitochondrial proteins and prevent mitochondrial protein synthesis, whereas damaged 
lipids and proteins result in impaired mitochondrial function, leading to further increases in mitochondrial 
ROS. ROS also activate nuclear factor erythroid 2-related factor 2 (NRF2), which translocates to the 
nucleus and binds to antioxidant-responsive elements (AREs) to activate the transcription of genes 
encoding oxidant-neutralizing enzymes, such as mitochondrial superoxide dismutase 2 (SOD2), glutathione 
peroxidase (GPX) and catalase. SOD2 reduces superoxide anions to hydrogen peroxide (H2O2) and oxygen 
(O2). Catalase, found in the cytoplasm, and GPX, located in the cytoplasm and mitochondria, reduce 
H2O2 to water (H2O)223. GPX also oxidizes glutathione (GSH), resulting in glutathione disulfide (GSSG) as 
a byproduct of reducing hydrogen peroxide to water. GSSG in mitochondria (mGSSG) is converted back to 
GSH by glutathione reductase (GR) in a process that requires the presence of NADPH. The activity of the 
mitochondrial uncoupling protein 2 (UCP2) is increased, dissipating the proton motive force and 
decreasing ROS production. mGSH, mitochondrial GSH. The electron transport chain complexes I–V are 
indicated as I, II, III, IV and V. From: Bhargava, P. & Schnellmann, R. G. (2017) Mitochondrial energetics 
in the kidney Nat. Rev. Nephrol. doi:10.1038/nrneph.2017.107 
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Another important antioxidant defense mechanism involves glutathione. Glutathione is a 
tripeptide (γ-glutamyl-cysteinal-glycine) nucleophile that can exist in a reduced form 
(GSH), or in the oxidized form as glutathione disulfide (GSSG). Mitochondria contain 
their own pool of glutathione, mGSH, which not only helps to decrease excessive ROS 
levels but also to prevent the release of cytochrome c from the inner membrane. mGSH 
directly interacts with superoxide anions and becomes oxidized to GSSG31. Glutathione 
peroxidase (GPx) is located in both the cytoplasm and the mitochondria, and uses GSH to 
reduce hydrogen peroxide to water, resulting in GSSG as a by-product32 . GSSG cannot 
exit the mitochondria and is converted back to mGSH, by glutathione reductase, for use 
again or eliminated from the mitochondria31. The conversion of GSSG to mGSH requires 
nicotinamide adenine dinucleotide phosphate (NADPH), allowing crosstalk between the 
mechanism that maintains mGSH levels and the pentose phosphate pathway that 
produces NADPH. Taken together, these mechanisms play a major role in preventing 
excessive levels of ROS to sustain mitochondrial function. 
 
Uncoupling proteins are a family of mitochondrial transport proteins located in the 
mitochondrial inner membrane33,34. They transport protons across the inner membrane to 
the mitochondrial matrix. Mitochondrial uncoupling protein 2 (UCP2) is expressed in the 
kidney and it is activated by mitochondrial ROS and other stimuli. An increase in ROS 
formation in the mitochondria activates UCP2, dissipating the proton motive force as heat 
and, as a result, reducing ROS production34,35. As ROS production contributes to 
mitochondrial dysfunction in AKI and diabetic nephropathy, UCP2 has been explored in 
the kidney and in these disease states36. Studies investigating the role of UCP2 gene 
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polymorphisms in the kidney that exacerbate disease in patients with diabetic 
nephropathy reveal that UCP2 is a potential target for treatment37. It was also reported 
that a lack of UCP2 worsened tubular injury after AKI in mice36. These studies show the 
importance of UCP2 in the kidney as well as its role in attenuating excessive ROS 
production.  
 
There are also mechanisms that sustain mitochondrial function under hypoxic conditions. 
The lack of oxygen under hypoxic conditions decreases ATP production and causes cell 
death. In normoxic conditions, hypoxia-inducible factor-1α (HIF-1α) is degraded in the 
presence of oxygen and α-ketoglutarate, an intermediate of the TCA cycle38. However, 
under hypoxic conditions HIF-1α heterodimerizes with HIF-1β to form a transcription 
factor that binds to a hypoxia response element (HRE) that is present in genes encoding 
glycolytic enzymes and glucose transporters in the kidney39. Hypoxic conditions also 
alter the composition of complex IV of the ETC in which, at physiological conditions, 
regulatory subunit 1 predominates in the ETC; during hypoxia regulatory subunit 2 
predominates in Complex IV, which increases the efficiency of the ETC40. Several 
studies have shown that increasing the efficiency of the ETC increases the production of 
mitochondrial ROS under hypoxic conditions, although this mechanism is still unclear41-
43. The effects of oxidative stress and hypoxia on mitochondrial morphology and 





Maintaining mitochondrial homeostasis 
 
Nutrient-sensing pathways in the kidney 
 
Nutrient-sensing pathways can directly affect mitochondrial energetics in response to 
external stimuli such as hypoxia, oxidative stress and energy depletion. Two signalling 
pathways in particular have been extensively explored in the kidney, namely the 
mechanistic target of rapamycin (mTOR) and AMP-activated protein kinase (AMPK) 
signalling pathways44,45. Both signalling pathways also have a role in regulating 
mitochondrial biogenesis (MB) — that is, the production of new and functional 















Figure 1.3: Crosstalk between two nutrient-sensing pathways 
Mechanistic target of rapamycin complex 1 (mTORC1) and AMP-activated protein kinase (AMPK) have 
key roles in regulating mitochondrial biogenesis and mitophagy. mTORC1 is responsible for triggering 
anabolic pathways, such as the synthesis of proteins, nucleotides and lipids, as well as mitochondrial 
biogenesis. AMPK activates catabolic pathways, including autophagy, mitophagy, fatty acid oxidation and 
glycolysis. AMPK can stimulate mitochondrial biogenesis (dotted arrow). However, in response to stimuli 
such as nutrient deprivation, AMPK can inhibit mTORC1 (dotted inhibitory line) and phosphorylate ULK1 
to activate mitophagy (dashed arrow). Together these two signalling pathways maintain cell function and 
sustain mitochondrial energetics in response to stimuli such as hypoxia, oxidative stress and energy 
depletion. From: Bhargava, P. & Schnellmann, R. G. (2017) Mitochondrial energetics in the kidney Nat. 














mTOR is a serine/threonine kinase that is made up of a complex of proteins. There are 
two distinct complexes of mTOR, mechanistic target of rapamycin complex 1 (mTORC1) 
and mTORC2, each of which contain their own unique subunits and substrates. 
mTORC1, a complex of mTOR, regulatory-associated protein of mTOR (Raptor) and 
several other proteins, regulates cell growth and proliferation and inhibits autophagy by 
stimulating anabolic processes. mTORC2, which is a complex of mTOR, rapamycin-
insensitive companion of mTOR (Rictor) and several other proteins, is thought to 
regulate potassium and sodium levels in the kidney46,47. mTORC1 is considered a nutrient 
sensor because it can be activated by growth factors, nutrients such as amino acids and 
glucose, and oxidative stress, triggering pathways that lead to protein synthesis, 
nucleotide synthesis, lipid synthesis, and MB by activating the transcriptional repressor 
yin-yang 1, (YY-1)44,48. In the case of MB, YY-1 acts as a transcription factor and 
coactivator of the master regulator of MB- the transcriptional coactivator peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) - resulting in the 
transcription of mitochondrial genes.48 mTORC1-decficiency specifically in renal 
proximal tubules of mice decreased the protein levels of PGC-1α , in vivo.49 Of note, the 
mTOR pathway can be inhibited by hypoxia and AMPK. 
  
AMPK is another nutrient sensor in the kidney that stimulates catabolic processes. When 
the AMP:ATP ratio in the cell is high in the presence of low oxygen levels, AMPK is 
activated. AMPK targets a number of proteins, the phosphorylation of which leads to the 
production of antioxidant enzymes, the induction of MB, and an increase in glycolytic 
flux, fatty acid oxidation and glucose transport; all of these events contribute to cell 
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growth and an increase in cellular metabolism50. AMPK can induce MB by stimulating 
the transcription of the gene encoding PGC-1α and by phosphorylating PGC-1α at 
threonine 177 and serine 539 to increase its activity51. AMPK stimulates the production 
of energy and inhibits energy-consuming pathways by inhibiting mTORC1. Under 
conditions of nutrient deprivation, crosstalk exists between mTORC1 and AMPK (FIG. 
3) so that AMPK can inhibit mTORC1 while activating autophagy by phosphorylating 
the serine/threonine-protein kinase ULK152. Due to its high number of targets in kidney 
cells, AMPK is a novel drug target for several diseases in the kidney (see below).  
 
Mitochondrial homeostasis is a balance between MB, fission and fusion, and mitophagy, 
the selective removal of non-functional and damaged mitochondria from cells by 
autophagy. All of these processes work in concert to maintain mitochondrial energetics, 
that is, the optimal production of ATP in normoxic conditions and in altered metabolic 




Mitochondrial biogenesis (MB), which produces new and functional mitochondria, 
increases ATP production in response to increasing energy demands. MB is regulated by 
an array of transcriptional coactivators and corepressors53,54. PGC-1α. was shown to be a 
prominent regulator, at the transcriptional level, of oxidative phosphorylation, the TCA 
cycle and fatty acid metabolism in the kidney55. The investigators performed gene 
expression profiling of kidneys from control mice and nephron-specific inducible PGC-
 17 
1α knockout (NiPKO) mice that had been fed a chow diet or high fat diet (HFD). Using 
the Kyoto Encyclopedia of Genes and Genomes (KEGG) database,[link to: 
http://www.genome.jp/kegg/] they analyzed transcripts from all four groups of mice. 
Interestingly, a decrease in transcripts related to oxidative phosphorylation, TCA cycle, 
and glycolysis was detected in chow-fed NiPKO mice and in HFD-fed NiPKO mice. This 
finding supports the idea that inactivation of PGC-1α in the kidney significantly reduces 
mitochondrial function and metabolism and subsequently decreases MB. 
 
It has also been shown that the overexpression of PGC-1α can mitigate mitochondrial 
dysfunction in vitro after oxidant exposure, further supporting a role for MB in 
mitochondrial homeostasis56. The activation of peroxisome proliferator-activated 
receptors (PPARs) and estrogen-related receptors (ERRs) also contributes to the 
regulation of MB, sometimes by directly interacting with PGC-1α57(FIG. 1.4). PPARs 
and ERRs are nuclear receptors that can be activated by fatty acids and steroid hormones 
such as estrogen, and they elicit a response by binding to specific DNA response 
elements through their DNA-binding domains58. PGC-1α can directly bind to these 
nuclear receptors and coactivate the transcription of genes for oxidative phosphorylation 
and fatty acid oxidation59,60. PGC-1α activation results in its translocation from the 
cytoplasm to the nucleus, allowing it to upregulate the transcription of genes, the protein 
products of which are important for mitochondrial homeostasis and ATP production61. 
Transcription programmes downstream of PGC-1α include nuclear and mitochondrial 




Figure 1.4: A complex network of pathways regulate mitochondrial biogenesis. Activation of 
peroxisome proliferator-activated receptor-γ co-activator 1α (PGC1α) in the cytosol causes its translocation 
to the nucleus and the transcription of genes (including that encoding mitochondrial transcription factor A 
(TFAM)), the protein products of which are needed for oxidative phosphorylation (oxphos), the 
tricarboxylic acid (TCA) cycle and mitochondrial biogenesis. TFAM aids in the transcription of genes that 
are encoded by mitochondrial DNA224,225,226. The activation of G protein-coupled receptors (GPCRs), 
such as the β2adrenergic receptors (β2AR) and 5-hydroxytryptamine receptor 1F (5-HT1F), leads to the 
dissociation of heterotrimeric G proteins composed of Gα, Gβ and Gγ subunits and the subsequent 
activation of protein kinase A and endothelial nitric oxide synthase (eNOS)66. The pathway from GPCRs 
to eNOS is still under investigation, as indicated by the dashed line. eNOS stimulates soluble guanylyl 
cyclase (sGC) to form cyclic guanosine monophosphate (cGMP), which in turn activates PGC1α. A 
number of compounds can activate nuclear receptors such as peroxisome proliferator-activated receptors 
(PPARs) and oestrogen- related receptors (ERRs) and induce mitochondrial biogenesis. Once activated, 
these nuclear receptors can act as transcriptional co-activators (labelled in the figure as nuclear receptor 
transcription factors (NRTFs)), with PGC1α to stimulate mitochondrial biogenesis. Other transcription 
factors, including nuclear respiratory factor 1 (NRF1) and NRF2, can also directly bind to PGC1α to induce 
mitochondrial biogenesis227. Stimuli, such as caloric restriction, can activate eNOS, increasing the 
production of cGMP and leading to the activation of PGC1α. The activity of sirtuin 1 (SIRT1) is increased 
in the presence of a high ratio of NAD+ to NADH concentrations, leading to the activation of PGC1α. High 
AMP:ATP ratios also activate AMP-activated protein kinase (AMPK), activating PGC1α by 
phosphorylation. In all of these cases, the activation of PGC1α stimulates mitochondrial biogenesis. Ac, 
acetyl; PDE5, cGMP-specific 3′,5′-cyclic phosphodiesterase; PKA, protein kinase A; sGC, soluble guanylyl 





As the activation or suppression of PGC-1α is regulated by external stimuli and post-
translational modifications it can be considered to be a nutrient sensor in the kidney.  
PGC-1α protein expression in the kidney and its role is still being explored. However, 
much of what is known has been discovered in diseased states in the kidney caused by 
different insults such as DN, ischaemia/reperfusion injury (IRI), sepsis, cisplatin-induced 
AKI, and others. Findings in the diseased states support a role for the importance of 
PGC-1α in the recovery phase from these diseases and for restoring mitochondrial 
function, highlighting PGC-1α as a therapeutic target. Exercise and insulin stimulates an 
increase in PGC-1α gene expression  in skeletal muscle and in the heart, whereas fasting 
will increase PGC-1α gene expression in the liver 62,65. In brown fat and muscle cells, 
cold exposure activates PGC-1α 62. In cases of oxidative stress or nutrient depletion, the 
activation of MB helps rescue mitochondria from apoptosis66,67. In general, if the cell is 
in need of more energy PGC-1α is activated by deacetylation; it is inactivated by 
acetylation when energy levels are high62.  
 
In addition to AMPK and mTOR, other energy sensing pathways that stimulate MB 
include those involving sirtuins, cyclic adenosine monophosphate (cAMP), and cyclic 
guanosine monophosphate (cGMP) (FIG. 1.4). NAD-dependent protein deacetylase 
sirtuin-1 (also known as SIRT1) and SIRT3 are protein deacetylases that play a role in a 
variety of mitochondrial processes, including the ETC, TCA cycle, fatty acid oxidation, 
redox homeostasis, and MB 68. SIRT1 is activated by NAD+, and it can then activate 
downstream targets such as PGC-1α61. SIRT3 is a mitochondria-specific sirtuin and it can 
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be activated to stimulate MB 69. The stimulation of adenylate cyclase results in an 
increase in cAMP, which activates protein kinase A (PKA) and, in turn, phosphorylates 
cyclic AMP-responsive element-binding protein (CREB)62,70. CREB is also a 
transcriptional activator of PGC-1α and therefore can also stimulate MB. Finally, 
increased levels of cGMP induced by caloric restriction and the inhibition of 
phosphodiesterase can stimulate PGC-1α activation and MB in vivo71-73. Several of these 
pathways are being targeted to increase MB to correct mitochondrial defects. 
 
Mitochondrial dynamics and energetics 
 
Mitochondrial morphology must be retained for maximal ATP production. The processes 
of fission, fusion and mitophagy drive mitochondrial dynamics as they directly impact  
mitochondrial structure and morphology. Fission and fusion complement each other 
under different metabolic conditions to maintain mitochondrial morphology, and 
mitophagy removes damaged mitochondria from the network74. Sustaining mitochondrial 
dynamics is important for retaining mitochondrial energetics.  
 
 
[H3] Fission and fusion.  
 
Fission, the splitting of mitochondria into two, and fusion, the combining of two 
mitochondria, are complementary processes necessary for mitochondrial homeostasis. At 
steady state there is a balance between these processes (FIG. 1.5). The genetic deletion of 
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genes, the protein products of which are involved in fission or fusion, causes human 
disease. For example, dominant optic atrophy is characterized by loss of visual acuity due 
to mutations in the gene encoding the fusion protein dynamin-like 120 kDa protein (also 
known as OPA1), and mutations in the gene encoding the fission protein dynamin-1-like 
protein (DRP1) are lethal 75-80. Although there are exceptions, in general, studies have 
shown that there is an increase in oxidative phosphorylation in fusion and a decrease in 
oxidative phosphorylation in fission to match the energy demands of the cells81,82. 
Excessive fusion, like excessive fission, can also be associated with diseased states as 
seen in neurodegenerative diseases83. There are certain cell types that do not adhere to 
this trend such as adult cardiomyocytes and senescent cells. Mitochondria in adult 
cardiomyocytes have fragmented morphology and still maintain oxidative capacity 
whereas mitochondria in senescent cells remain elongated, characteristic of increased 








Figure 1.5: Mitochondrial dynamics: fission, fusion and mitophagy 
Mitochondria are dynamic organelles that need to maintain their morphology for the optimal production of 
ATP under different metabolic conditions and as part of a healthy network of mitochondria. Fission and 
fusion are two processes that are necessary for the maintenance of mitochondria morphology. Mitochondria 
fuse together via mitofusin 1 (MFN1) and MFN2 (outer membrane fusion) and the activation of dynamin-
like 120 kDa (OPA1) (inner membrane fusion). Fusion can occur to maintain ATP production or to 
redistribute mitochondrial proteins. Fission can isolate depolarized mitochondrion that might not contribute 
to the healthy network of mitochondria. The activation of fission causes the oligomerization of dynamin 1-
like protein (DRP1) on the mitochondrial outer membrane, where it is bound to receptors (namely 
mitochondrial fission 1 (FIS1) and mitochondrial fission factor (MFF)), forming a ring-like structure that 
mediates the separation of mitochondria. The network also isolates dysfunctional mitochondria for 
degradation by mitophagy via a well-studied PTEN-induced putative kinase 1 (PINK1)–PARKIN 
mechanism. Under adverse conditions such as hypoxia, however, mitochondria will be removed by a 
FUN14 domain-containing protein 1 (FUNDC1) or BCL2/adenovirus E1B 19 kDa protein-interacting 
protein 3 (BNIP3) and NIP3-like protein (NIX)-dependent mechanism of mitophagy. LC3, microtubule-
associated protein 1 light chain 3; Ub, ubiquitin. From: Bhargava, P. & Schnellmann, R. G. (2017) 





Fusion is a two-part process that involves fusing the outer mitochondrial membrane, and 
subsequently the inner mitochondrial membrane, of two mitochondria. GTPases of the 
dynamin superfamily — Mitofusin-1 (MFN1), MFN2, and OPA1 — are key players in 
fusion. MFN1 and MFN2 are located on the outer mitochondrial membrane and 
necessary for outer membrane fusion, whereas OPA1 resides in the inner membrane and 
is important for inner membrane fusion. Fusion leads to elongation of mitochondria under 
physiological conditions, which can help to maintain oxidative phosphorylation87. These 
GTPases can play a role in mitochondrial energetics. For example, the deletion of MFN2 
in mice causes a deficiency in coenzyme Q, an electron carrier in Complex III, which 
causes a deficiency in the ETC and a decrease in ATP production88. Activation of these 
mitofusins and the cleavage of Opa1 can be regulated by changes in metabolism (see 
below).  
 
Mitochondrial outer membranes are tethered by MFN1 and MFN2 dimerization and 
external stimuli such as oxidative stress can enhance outer membrane fusion89. The 
activation of inner membrane fusion can be regulated by changes in metabolism at the 
sites of proteolytic cleavage of OPA190. OPA1 usually exists in a soluble long form and it 
can be cleaved by the ATP-dependent zinc metalloprotease YME1L or by the 
metalloendopeptidase OMA1, which is activated in response to a loss in membrane 
potential, to yield a soluble short form82. The soluble long and short forms are necessary 
for fusion to occur. During steady state, both can coexist to impart minor structural 
remodeling of mitochondria91,92 The activation of cleaved OPA1 requires the presence of 
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GTP and the availability of GTP to activate OPA1 correlates with ATP levels in the 
cell93,94. The exact mechanism by which outer membrane and inner membrane fusion 
events are coordinated is still under investigation.  
 
Fission is necessary to isolate damaged mitochondria from the network. The resulting 
daughter mitochondria may be unbalanced and the depolarized daughter mitochondrion is 
targeted for mitophagy95 to sustain a population of healthy mitochondria (see below). 
However, excessive fission, as seen in diseases such as DN and AKI, can have harmful 
effects on mitochondrial homeostasis long term96. In vitro studies have been conducted to 
elucidate the mechanisms that trigger mitochondrial fission. Cells exposed to an excess of 
nutrients or oxidative stress have fragmented mitochondria96. Fission is induced by the 
translocation of DRP1 from the cytosol to the mitochondrial outer membrane as a result 
of a loss in mitochondrial membrane potential. If the membrane potential is not restored, 
mitochondria will be degraded via mitophagy96. DRP1 oligomerizes on the outer 
membrane to form a ring like structure around the mitochondria that can cause scission of 
the membrane97. DRP1 can bind to several different receptors, such as mitochondrial 
fission 1 (FIS1), mitochondrial dynamics proteins MID49 and MID51, and mitochondrial 
fission factor (MFF) that reside on the outer membrane78. DRP1 accumulates on the outer 
mitochondrial membrane by binding to these receptors and mediates the scission of 
mitochondria, a GTP dependent process98. MID51 contains a cytosolic domain with 
affinity for ADP and GDP, and can therefore act as a metabolic sensor99,100. DRP1 
activity can be regulated by post-translational modifications such as phosphorylation, 
ubiquitylation, and sumoylation101, and several  signalling pathways have been shown to 
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regulate the phosphorylation of DRP1102. For example, phosphorylation of DRP1 at 
Ser637 by PKA inhibits its GTPase activity and, thus, inactivates fission78,103. By 
contrast, dephosphorylation of DRP1 at Ser637 by calcium and calmodulin dependent 
serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform or calcineurin 
(CaN) activates DRP1 and promotes fission104,105. The balance between fission and fusion 
to maintain a functional population of mitochondria is an intricate process and is still 
under investigation. However mitochondria, such as damaged mitochondria, that disrupt 





Mitophagy in most cell types is regulated by the PTEN-induced putative kinase 1 
(PINK1)–PARKIN mechanism that tags mitochondria for degradation106. PINK1, a 
kinase that is located in the mitochondria, is imported into the mitochondria and then 
degraded under physiological conditions107. As protein import is dependent on the 
mitochondrial membrane potential, mitochondrial depolarization results in the 
accumulation of PINK1 on the outer membrane; the PINK1-mediated phosphorylation of 
certain proteins here mediates the recruitment of the E3 ligase PARKIN108-111 to the outer 
membrane. PARKIN attaches ubiquitin to lysine residues in the N termini of 
mitochondrial outer membrane proteins, such as MFN1 and MFN2, which targets the 
mitochondria for degradation by autophagosomes112-116.  
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Several pathways regulate mitophagy (FIG. 1.5). Proteins that are important for 
autophagy, such as ULK1 and ULK2, can mediate mitophagy under different stimuli117. 
For example, when nutrients are sufficient, AMPK is inhibited and mTOR inhibits 
ULK1, suppressing mitophagy118. During nutrient deprivation, AMPK is activated and 
inhibits mTOR, allowing for ULK1 activation and mitophagy117 (FIG. 3). Under 
oxidative stress, AMPK can be activated and inhibit mTOR, again activating 
mitophagy52,118. A more direct role for AMPK in the activation of mitophagy has also 
been suggested119. The authors of this study proposed that AMPK directly phosphorylates 
MFF on Ser155 and Ser172, triggering fission and, subsequently, mitophagy120. 
However, external stimuli that trigger this pathway are unknown and more research is 
needed.  
 
Other stimuli, such as hypoxia, cause the serine/threonine-protein phosphatase PGAM5 
to dephosphorylate its substrate, the mitophagy receptor, FUN14 domain-containing 
protein 1 (FUNDC1)121. FUNDC1 then interacts with microtubule-associated protein 1 
light chain 3 (LC3), which mediates the formation of an autophagic membrane121,122. 
Alternatively, hypoxia can induce mitophagy through the actions of BCL2/adenovirus 
E1B 19 kDa protein-interacting protein 3 (BNIP3) and BCL2/adenovirus E1B 19 kDa 
protein-interacting protein 3-like - (NIX) via a mechanism that involves HIF-1α123,124. 
HIF-1α can directly induce the transcription of BNIP3 and NIX by binding to the 
promoter of the gene encoding BNIP3 and by recruiting other coactivator proteins to the 
gene encoding NIX. NIX and BNIP3 are transmembrane proteins located in the 
mitochondrial outer membrane and they can activate mitophagy by dissipating the 
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mitochondrial membrane potential and interacting with LC3 to deliver mitochondria to 
the autophagosome124-127. BNIP3 and NIX are also apoptotic regulators that can induce 
cell death or autophagy by increasing the production of ROS, binding to pro-apoptotic 
proteins of the BCL2 family, or by inhibiting the GTP-binding protein RHEB, an 
upstream activator of mTOR128-130. Previous studies suggest that crosstalk exists between 
both of the mechanisms that can regulate mitophagy124,131,132, although the mechanisms of 
this proposed crosstalk are unclear and additional studies are needed to determine the 
mechanisms that regulate mitophagy in renal diseases.  
 
 
[H1] Mitochondria and renal diseases  
 
Diseases such as Acute Kidney Injury (AKI) and Diabetic Nephropathy (DN) can cause 
an imbalance in mitochondrial homeostasis, negatively impacting mitochondrial 
energetics or the production of ATP. Much research has recently supported the role for 
mitochondrial dysfunction in a number of renal diseases such as CKD, diabetes, and 
glomerular diseases133. Although this dissertation will focus on AKI, we include both 
AKI and DN as examples of how mitochondrial dysfunction can negatively impact 
mitochondrial energetics to contribute to disease progression.  
 
 
[H2] Acute kidney injury 
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The outcome of AKI is renal dysfunction, as indicated by an increase in blood urea 
nitrogen (BUN) and serum creatinine, and/or reduced urinary output 134. However in the 
last two decades the criteria for identifying renal dysfunction caused by AKI has been 
continuously reassessed beginning with establishment of the risk, injury, failure, loss, and 
end-stage renal disease (RIFLE) criteria in 2004135. The AKI network (AKIN) included 
the absolute change in serum creatinine and modified the RIFLE criteria136. In recent 
years, both sets of criteria were combined to establish the 2012 Kidney Disease: 
Improving Global Outcomes (KDIGO) as shown in Figure 1.6137. This criterion describes 
three stages of AKI based on serum creatinine and urinary output. Although this criteria 
may prove to be more useful compared to those used in the past, ultimately, the treatment 
of AKI depends on its pathogenesis, cause of onset, and efficient early detection methods.  
 
The pathogenesis is complicated and the onset is multifactorial138,139. Over the years, the 
incidence of AKI has increased and the mortality rate for patients that require renal 
replacement therapy is over 60%134,140-143. Ultimately, unresolved AKI can cause long 
term damage to the kidney, increasing the risk of chronic kidney disease (CKD)144. The 
etiology of AKI can be categorized as prerenal, postrenal, and intrinsic AKI139. Prerenal 
AKI is reversible and a cause of dysfunctional blood flow and glomerular hydrostatic 
pressure resulting in decreased filtration capacity145. Post renal AKI is a direct result of 
an obstruction of urinary flow and requires an ultrasound or equivalent methods to 
identify the obstruction of one or both ureters145,146. The pathophysiology of intrinsic AKI 
can result from sepsis, ischaemia–reperfusion injury (IRI), exposure to nephrotoxic 
reagents and trauma147. AKI can also result as a secondary insult in response to decreased 
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cardiovascular function148,149. One of the main sites of injury in AKI is the proximal 
tubules, which is characterized by disrupted brush borders and tight junctions, cell 
sloughing, apoptosis, necrosis, and the subsequent backleak of filtrate across injured 
proximal tubular cells150.  
 
Current detection methods, although are useful, are not efficient or accurate for detecting 
AKI in its early stages, prior to when KDIGO standards are applied. Current methods 
include testing for Kidney Injury Marker-1, KIM-1, and neutrophil gelatinase-associated 
lipocalin (NGAL). Both proteins are released from proximal tubules whereas NGAL can 
also be released from the distal tubule and both can be measured in the urine. Expression 
for NGAL can be detected 3 hours after injury whereas KIM-1 can be measured up until 
24 hours after insult145. The release of KIM-1 and NGAL suggests that both proteins play 
a role in activating the immune system after injury145. KIM-1 triggers pathways necessary 
for the clearance of dead cells and remodeling of injured cells whereas NGAL can 















Class  GFR  UO  
Risk  ↑ SCr × 1.5 or ↓ GFR >25%  
<0.5 mL/kg/h × 6 
h  
Injury  ↑ SCr × 2 or ↓ GFR >50%  
<0.5 mL/kg/h × 12 
h  
Failure  
↑ SCr × 3 or ↓ GFR >75% or if baseline SCr 
≥353.6 μmol/L(≥4 mg/dL) ↑ SCr >44.2 
μmol/L(>0.5 mg/dL)  
<0.3 mL/kg/h × 24 
h or anuria × 12 h  
Loss of kidney 
function  Complete loss of kidney function >4 weeks    
End-stage 
kidney 
disease  Complete loss of kidney function >3 months    
aGFR, glomerular filtration rate; UO, urine output; SCr, serum creatinine. 
 
Figure 1.6: Risk, Injury, Failure, Loss of kidney function and End-stage kidney disease 
(RIFLE) classification. From: Hertzberg, D., Rydén, L., Pickering, J. W., Sartipy, U. & 
Holzmann, M. J. Acute kidney injury-an overview of diagnostic methods and clinical 


















Much research has been conducted on mitochondrial dysfunction as an initiator and 
contributor of renal injury and as a therapeutic target153,154 (Figure 1.7). Histologically, 
mitochondrial swelling and fragmentation are observed after diverse insults to the 
kidney154. A decrease in ATP production, an increase in ROS production, the release of 
cytochrome c, and the disruption of mitochondrial cristae are also observed, supporting a 
role for mitochondria in AKI 154. A decrease in ATP production and mitochondrial 
dysfunction has been documented in many animal models of AKI, including sepsis, and 
these outcomes result from the loss of mitochondrial respiratory proteins in proximal 
tubules 155-157. Furthermore, the loss of ETC proteins is persistent in the damaged kidney 
and this may contribute to the slow recovery of renal function after AKI155. 
 
In the ischemic kidney, a number of factors disrupt the oxidation and transport of fatty 
acids, causing an accumulation of fatty acids in the cytoplasm and, subsequently, 
contributing to the decrease in ATP production and mitochondrial 
energetics158,17,154,159,160. For example, cofactors such as NAD+ are necessary for fatty 
acid oxidation but a dysfunctional ETC is not able to regenerate NAD+ 161. IRI also 
decreases the activity of CPT117,162, the rate-limiting enzyme in the carnitine shuttle that 
transports fatty acids from the cytoplasm into the mitochondria162. This decreases the 









Figure 1.7: Mitochondrial injury and recovery during acute kidney injury (AKI) 
From: Emma, F., Montini, G., Parikh, S. M. & Salviati, L. Mitochondrial dysfunction in 









After IRI increased levels of lactate and pyruvate and of hexokinase activity in the kidney 
were reported, suggesting that there is an increase in glycolysis after injury163,164. 
Increased levels of glycolytic enzymes were also detected in injured renal tubules after 
IRI165,166. Thus, the kidney can respond to injury by altering its metabolic substrates to 
maintain function167. Further studies are needed to explore how this increase in glycolysis 
affects mitochondrial function in the kidney and if this change in metabolism contributes 
to recovery following IRI long term.  
 
Another major contributor to the decrease in mitochondrial energetics seen in AKI are 
changes in mitochondrial dynamics168 (FIG. 1.8). The translocation of DRP1 into the 
mitochondrial outer membrane occurs shortly after kidney injury155,169. Activation of 
DRP1 in ischemic kidneys promotes mitochondrial fragmentation and apoptosis170. Loss 
of cristae structure is also observed in AKI, dissipating the mitochondrial membrane 
potential and halting ATP production154. Administration of a pharmacological inhibitor of 
DRP1, mdivi-1, protected kidneys from AKI by inhibiting mitochondrial fragmentation, 
supporting a role for altered mitochondrial dynamics in AKI169.  
 
Mitophagy is also activated after ischemic AKI. In mice where autophagy regulator 
autophagy-related (ATG) 7 and ATG5 were specifically knocked out in renal proximal 
tubules, mitochondrial dysfunction was greater in renal proximal tubules in response to 
IRI, as characterized by severe morphological changes, increased ROS production and 
apoptosis171-173. The activation of NIX and BNIP3 causes the release of ROS and of the 
pro-apoptotic proteins BAX and BAK, in hypoxic conditions113,174. Deletion of BAX and 
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BAK in mouse kidneys not only protected mice from ischemic AKI but also suppressed 
the release of Cytochrome c and mitochondrial fragmentation, preserving mitochondrial 
integrity175. The lack of ATG7, also exacerbated cisplatin-induced AKI in mice131,171. 
These studies suggest that there is crosstalk between the mechanisms of cell death and 
autophagy in the activation of mitophagy.  
 
The role of SIRT3 in cisplatin-induced AKI has also been explored. SIRT3 is a 
mitochondrial specific protein deacetylase with an active role in mitochondrial function 
and integrity176. An in vitro study using cisplatin-injured human renal proximal tubules 
showed that the overexpression of SIRT3 decreased the translocation of DRP1 from the 
cytosol to the mitochondrial outer membrane and thus, mitochondrial fission, providing a 
role for SIRT3 in regulating mitochondrial dynamics after AKI176. The deletion of SIRT3 
exacerbates injury in a cisplatin-induced AKI mouse model, supporting its role in the 
recovery from this disease176.  
 
In mouse models of AKI, the transcription and protein expression of PGC-1α are 
suppressed persistently but are eventually restored to basal levels in models of AKI 
recovery155. As PGC-1α can regulate the transcription of mitochondrial proteins, the level 
of these proteins is also decreased after AKI155,177.. In a model of septic AKI, global 
PGC-1α knockout mice showed a greater increase in BUN and creatinine levels than 
wild-type mice156. Renal specific PGC-1α knockout mice exhibited persistent AKI156. In 
contrast, the overexpression of PGC-1α in renal proximal tubule cells attenuates oxidant 
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injury in vitro 56. Together, these studies show that PGC-1α is necessary for the recovery 
of renal function in AKI.  
 
Investigations into the mechanisms by which PGC-1α regulates the recovery from AKI 
revealed a role for PGC-1α in NAD biosynthesis. Levels of nicotinamide, a precursor for 
NAD, were decreased after AKI in PGC-1α knockout mice and supplementation with 
nicotinamide reversed ischemic AKI178. We have reported that drugs/chemicals can 
upregulate MB by increasing PGC-1α protein expression in the recovery phase following 
IRI through two classes of G-protein coupled receptors (GPCRs): the β2 adrenergic 














Figure 1.8: Changes in mitochondrial morphology lead to tubular damage in acute kidney injury 
A healthy proximal tubule consists of an intact brush border with tight junctions and contains a network of 
mitochondria to maintain its function. After ischaemia–reperfusion injury (IRI), changes in mitochondrial 
function and morphology lead to mitochondrial dysfunction, and eventually to injured proximal tubules. In 
the early stages of acute kidney injury (AKI), a number of events may happen concurrently to cause a 
decrease in ATP production. These events include a decrease in the expression of carnitine O-
palmitoyltransferase 1 (CPT1) (causing fatty acid accumulation and decreasing β-oxidation for ATP 
production), a decrease in the expression of peroxisome proliferator-activated receptor-γ co-activator 1α 
(PGC1α) and an increase in the production of reactive oxygen species (ROS) (bidirectional arrows). 
Together, these events can trigger the activation and accumulation of dynamin 1-like protein (DRP1) on the 
mitochondrial outer membrane, promoting mitochondrial fragmentation and eventually cell death. The 
release of cytochrome c and mitochondrial DNA (mtDNA) from dysfunctional mitochondria causes an 
increase in mitophagy. Mitochondrial dysfunction can induce cell death in injured proximal tubules, 
resulting in the loss of nuclei and tight junctions and in disrupted brush borders. Apoptotic or necrotic 
tubules can lead to cell sloughing, as seen in the centre of the tubule. From: Bhargava, P. & Schnellmann, 








 [H2] Diabetic nephropathy 
 
DN is the leading cause of end-stage renal disease (ESRD) in the United States181,182. It is 
characterized by an increase in hyperglycemia, albuminuria, the accumulation of 
extracellular matrix proteins and glomerular and tubular epithelial hypertrophy, as well as 
a reduced glomerular filtration rate (GFR)183. Mitochondrial energetics are altered in DN 
due to a combination of increased ROS and hyperglycemia184, both of which induce 
changes in the ETC that cause a decrease in ATP production and an increase in 
apoptosis184. In line with these observations, increased fission, mitochondrial 
fragmentation, and reduced levels of PGC-1α are all observed in the early stages of 
diabetes185,186. Structural changes in mitochondria correlate with the changes seen in 
energetics186.  
 
Hyperglycemia is the main contributing factor of DN (FIG. 1.9). Hyperglycemia 
increases the production of NADH and FADH2 by the TCA cycle, fueling the ETC. ROS 
released from the ETC can damage mtDNA, hindering the production of mitochondrial 
proteins187. Originally it was thought that the excess glucose in hyperglycemia creates 
hyperpolarized mitochondria that produce more ATP and release superoxide from 
complexes I and III, causing mitochondrial dysfunction184,188,189. However, administering 
antioxidants such as vitamin E and vitamin A did not attenuate the complications seen in 
patients with diabetes, suggesting that mitochondrial ROS may not be the primary 
mediator of mitochondrial dysfunction in DN190. Hyperglycemia can also increase the 
level of advanced glycation end (AGE) precursors, the activity of the protein kinase C 
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(PKC) and hexosamine pathways, which can contribute to mitochondrial dysfunction191. 
All three events cause deleterious effects that include increased fibrosis, thrombosis, 
oxidative damage, and abnormalities in vasculature and blood flow191.  
 
Hyperglycemia also causes the conversion of glucose to fructose via the polyol pathway 
in proximal tubules, leading to ATP depletion192. A role for endogenous fructose 
metabolism in the regulation of DN was suggested by a study showing that knocking out 
the gene encoding fructokinase (KHK-/- mice), the enzyme responsible for the conversion 
of fructose to fructose-1-phosphate, in mice, protected them from DN induced by 
streptozotocin193. Proximal tubules are a major site of fructokinase expression192,194 and 
ATP levels were increased and tubular morphology was improved in KHK-/- diabetic 
mice compared to wild type mice, suggesting a role for fructose metabolism in the 
pathogenesis of DN193.  
 
Mitochondrial fragmentation has been observed in proximal tubules in the early stages of 
diabetes 185, although the mechanisms that drive changes in mitochondrial dynamics in 
diabetes are still not clear. Fission dissipates the mitochondrial membrane potential, 
decreasing the production of ATP and promoting apoptosis195. Several studies have 
suggested a role for Rho-associated protein kinase 1 (ROCK1) signalling in activating 
fission in the diabetic kidney196. ROCK1 promotes the translocation of DRP1 to the 
mitochondria and triggers fission by phosphorylating DRP1196. Deletion of ROCK1 in 
streptozotocin-induced diabetes prevents fission, attenuates the increase in ROS 




In patients with diabetes, reduced levels of the fusion protein MFN2 were discovered197. 
In line with this finding, in kidneys from rats with streptozotocin-induced diabetes, the 
overexpression of MFN2 has a protective role in DN197. MFN2 overexpression decreased 
ROS production, decreased kidney volume and attenuated the pathological changes seen 
in the diabetic kidney197. Another protein that plays a role in fusion is called induced-in-
high glucose 1 (IHG-1). Studies have reported that IHG-1 is a regulator of mitochondrial 
dynamics and biogenesis in the diabetic kidney198. IHG-1 can enhance the ability of 
MFN2 to bind to GTP and it directly interacts with MFN2 to mediate fusion198. Inhibition 
of IHG-1 reduces ATP production and hinders fusion in vitro198. IHG-1 has also been 
found to stabilize PGC-1α activation199.  
 
Reduced levels of PGC-1α were also observed in diabetic rat kidneys200. The 
overexpression of PGC-1α in mesangial cells in vitro attenuated the pathophysiological 
changes induced by hyperglycemic conditions200. The decrease in  MB in diabetic rat 
kidneys is consistent with the translocation of DRP1 to the mitochondrial outer 
membrane and an increase in mitochondrial fragmentation200. It was also shown that the 
levels of PGC-1α mRNA and protein were reduced in podocytes cultured in 
hyperglycemic conditions compared to in podocytes cultured under normal glucose 
conditions, indicating a decrease in MB201.  
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Another study recently reported the importance of pyruvate kinase M2 in DN. In diabetic 
patients that have not developed DN, pyruvate kinase M2 (Pkm2) expression and activity 
is upregulated but not in DN patients202. Investigators observed a decrease in PGC-1α 
mRNA and mitochondrial mass in Pkm2-knockdown podocytes202. Activation of Pkm2 
attenuated the decrease in mitochondrial function and glycolytic flux in podocytes in 
vitro. In vivo studies showed that the activation of Pkm2 in mice attenuated the decrease 
in PGC-1α mRNA and increased the expression of OPA1, increasing fusion202. As such, 
activation of Pkm2 can reverse mitochondrial dysfunction and therefore renal 
abnormalities delaying the progression to DN. These studies show the need for more 
research, as targeting the balance between MB and dynamics could be a potential 
therapeutic target for DN.  
 
Mitochondrial dysfunction is a major contributor to the progression of renal disease, in 
particular AKI and DN, as described above and shows promise as a potential target for 











Fig 1.9: Factors contributing to mitochondrial dysfunction in diabetic nephropathy Hyperglycaemia is 
the primary contributing factor to mitochondrial dysfunction in diabetic nephropathy. An increase in 
glucose level results in an increase in glycolysis, in turn activating the advanced glycation end product 
(AGE) pathway, the protein kinase C (PKC) pathway and the hexosamine pathway, which results in a 
decrease in ATP levels. Hyperglycaemia also activates the polyol pathway, which increases fructose levels 
and, consequently, decreases ATP levels. Mitochondrial fragmentation and swelling is observed in early 
diabetic nephropathy, leading to an increase in fission and the production of reactive oxygen species 
(ROS). The correlations between increased mitochondrial fragmentation and decreased ATP, and between 
ROS production and decreased ATP, are interdependent. Whether one causes the other is unclear, as 
depicted by the bidirectional arrows. Decreases in the levels of mitofusin 2 (MFN2) and peroxisome 
proliferator-activated receptor-γ co-activator 1α (PGC1α) correlate with, and might contribute to, the 
increase in mitochondrial fission observed in diabetic nephropathy, as indicated by the larger arrows 
pointing towards increased mitochondrial fission. Decreases in mitochondrial energetics that are caused by 
changes in mitochondrial morphology and hyperglycaemia lead to apoptosis in diabetic nephropathy. F6P, 
fructose-6-phosphate; G6P, glucose-6-phosphate; G3P, glyceraldehyde-3-phosphate. From: Bhargava, P. & 








[H1] Mitochondrial energetics and therapy  
 
[H2] Targeting AMPK signaling 
 
AMPK signalling has been implicated as a target for correcting metabolism and 
mitochondrial function, especially in the kidney. As mentioned before, AMPK is a 
metabolic sensor for ATP in the cell. High AMP/ATP activate AMPK to stimulate cell 
growth and cellular metabolism. The AMPK activator 5-aminoimidazole-4-carboxamide-
1-β-d-riboside (AICAR), prevents glomerulopathy and tubulointerstitial fibrosis in mice 
by stimulating fatty acid oxidation (FIG 1.10)203. AICAR also has a therapeutic effect in 
mouse renal IRI and can improve glucose utilization in obese, insulin-resistant rats204,205. 
The activation of AMPK by AICAR increased the level of PGC-1α levels and of 
mitochondrial proteins while reducing ROS production in a diabetic mouse model206.  
 
Several studies have suggested that there is crosstalk between AMPK activation and 
SIRT3 signalling 207,208. SIRT1 and SIRT3 are activated by NAD+. In cisplatin treated 
mice, SIRT3 gene and protein expression were decreased, tubular damage was increased, 
and the level of phosphorylated AMPK was decreased compared to control mice treated 
with saline.209. The administration of AICAR, to cisplatin treated mice attenuated the 
decrease in SIRT3 protein and gene expression, the level of phosphorylated AMPK, and 
tubular damage209. These studies provide a therapeutic role for targeting AMPK 
signalling in the kidney for improved outcomes in AKI and DN.  
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[H2] Targeting PPARs 
 
As PPARs can regulate cellular metabolism, mitochondrial function, MB, fatty acid 
oxidation and glucose homeostasis, targeting them for treatment for renal diseases could 
be beneficial.  
 
The activation of PPARs can play a role in ameliorating ischemic AKI210-212. As 
discussed previously, an accumulation of fatty acids and increased ROS production can 
decrease the efficiency of the ETC. Defects in fatty acid oxidation were attributed to the 
down regulation of PPARs during renal ischemia17. Fenofibrate, a drug used for treating 
dyslipidemia, activates PPARα (Figure 1.10)213. The downstream effect of targeting 
PPARα is the activation of lipoprotein lipase, which hydrolyzes triglycerides into 
glycerol and free fatty acids for metabolism213. PPARs can also stimulate MB; for 
example, compounds such as bardoxolone increase the level of PPARγ and NRF2 
mRNA, leading to MB214. However, the use of bardoxolone in clinical trials for type 2 
diabetes and stage 4 CKD showed adverse effects in patients including an increase in 
heart failure events and led to the termination of the trial215.  
 
PPARs agonists also show promise as treatment for DN based on their efficacy in animal 
models. Previously, studies treating db/db diabetic mice with fenofibrate showed that it 
decreased hyperglycemia and insulin resistance, potentially by correcting glucose 
homeostasis.216 Studies have also shown a decrease in fatty acids in the kidney upon 
treatment of a diabetic mouse model with fenofibrate, supporting its potential as a 
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therapeutic for DN217-219. These in vivo studies provide evidence that fenofibrate might be 
suitable to treat patients with DN. Indeed, fenofibrate decreased dyslipidemia and 
albuminuria in patients with type II diabetes and reduced further cardiovascular events220. 
Taken together, these studies confirm that PPARs have a role in DN and are a therapeutic 
target.  
 
[H2] Targeting G protein-coupled receptors 
 
Although a wide variety of GPCRs are expressed in the kidney, few studies correlate 
GPCRs with mitochondrial function in the kidney and other organs. We proposed that 
compounds that target two different classes of GPCRs — β-2 adrenergic receptors 
(β2AR) and 5-hydroxytryptamine receptor 1F (5-HT1F) receptors— can induce MB, 
restore mitochondrial function and stimulate the recovery of renal function following IRI. 
Formoterol, a β2AR agonist used to treat asthma and chronic obstructive pulmonary 
disease, stimulates MB and the expression of PGC-1α in renal proximal tubular cells  and 
in mice221. The administration of formoterol in a model of IRI AKI following renal injury 
accelerated the recovery of mitochondrial and renal function by six days221. LY344864 is 
a potent agonist for 5-HT1F  receptors and it induced MB in naïve mice and accelerated 
the recovery of MB and renal function in the same AKI model180. There are currently 
several agonists of GPCRs in clinical trials for the treatment of DN, such as atrasentan; 
however, whether they act by influencing mitochondrial energetics is unknown and 
requires further research. These studies provide a foundation for pursuing the targeting of 
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GPCRs, particularly β2AR and 5-HT1F, as a treatment for mitochondrial dysfunction in 
renal diseases.  
 
[H2] Using mitochondrial peptides 
 
Recently a family of peptides called Szeto-Schiller peptides (SS peptides) were found to 
specifically target cytochrome c activity in the ETC, enhancing its efficiency and 
increasing ‘state 3 respiration’ — that is, ATP production in the presence of excess 
substrates and ADP222. SS peptides are highly polar, water soluble tetrapeptides that can 
cross the blood–brain barrier and specifically target the inner mitochondrial membrane. 
The SS peptides do not cause mitochondrial depolarization upon entry, making these 
compounds highly promising for treatment. SS peptides prevent the peroxidation of 
cardiolipin, a phospholipid important for maintaining cristae formation, by cytochrome 
c222. Cytochrome c binds and oxidizes cardiolipin, disrupting cristae formation and 
detaching cytochrome c from the inner mitochondrial membrane223,224. The SS-31 peptide 
has been shown, in a variety of animal disease models, especially in AKI, to promote 
ATP recovery and cristae formation222. Pre-treatment of rats with SS-31 in vivo 
maintained cristae formation and prevented mitochondrial swelling of renal tubular 
epithelial cells222. Due to the success in animal models, SS-31, which is also known as 






Figure 1.10: Approaches to correct abnormal mitochondrial function in AKI and 
diabetic nephropathy 
From: Bhargava, P. & Schnellmann, R. G. (2017) Mitochondrial energetics in the kidney 













Soluble Guanylyl Cyclase  
 
Nitric oxide, NO, is a small gaseous, nonpolar molecule that has been studied since the 
1980’s. Robert Furchgott discovered that the relaxation of blood vessels needs 
endothelial cells and that smooth muscles cells alone could not exhibit these effects226. 
Furchgott proposed that endothelial cells are secreting endothelial derived relaxing factor, 
EDRF, which is necessary for blood vessel relaxation226. Meanwhile, while elucidating 
the mechanism of action of nitroglycerin, Ferid Murad discovered that nitroglycerin 
causes the release of NO and that this causes the relaxation of smooth muscle cells227. 
Ignarro showed that EDRF and NO are the same molecule, piecing together the work of 
Murad and Furchgott228. Simultaneous work by these scientists resulted in a Nobel Peace 
Prize in physiology in 1998.  
 
NO is produced by nitric oxide synthase (NOS). There are three types of NOS: 
endothelial (eNOS), neuronal (nNOS), and inducible (iNOS). NO is produced by 
oxidizing L-arginine to L-citrulline and requires Ca2+ as a cofactor, tetrahydrobiopterin 
(BH4), and NADPH to accomplish this task229. The main receptor for NO is Guanylyl 
Cyclase (GC). There are two forms of GC, soluble GC (sGC) and membrane bound 
particulate GC (pGC). sGC is found in the cytosol of most cell types and is the primary 
receptor for NO. The family of pGCs contain up to six identified isoforms termed as GC-
A to GC-F230. Although both sGC and pGC have the same function in terms of 
converting GTP to cGMP, for the remainder of this dissertation, the focus will be on 
sGC.  
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sGC is a 150kD heterodimer consisting of the alpha and beta subunits. There are two 
types for each subunit. Depending on the cell type, different combinations of sGC 
heterodimers may exist as α1β1, α1β2, and α2β1
231,232. The α1β1 heterodimer is found in 
most mammalian tissues including the heart and kidney. The sGC heterodimer consists of 
the heme-nitric oxide oxygen domain (H-NOX), PAS domain, coiled-coil domain, and 
cyclase domain, Figure 1.11233. The β1-subunit is the catalytic subunit of sGC and 
contains the heme moiety bound to the residue, Histidine-105, located in the H-NOX 
domain at the N terminus of the β1-subunit
234. NO binds to the heme moiety in the β1-
subunit causing a conformational change in the enzyme resulting in a pentacoordinated 
Fe-NO complex235. This conformational change causes a break between Histidine-105 

















Figure 1.11: sGC domain structure. Shown are the approximate boundaries for each domain in sGC. 
Numbering is for the α1 and β1 subunits of human sGC. sGC, soluble guanylyl/guanylate cyclase. From : 
Montfort, W. R., Wales, J. A. & Weichsel, A. Structure and Activation of Soluble Guanylyl Cyclase, the 


















NO-dependent mechanisms operate primarily through sGC and pGC as described above 
and they involve cGMP to elicit most their effects. However, NO-independent 
mechanisms also exist and play a prominent role in disease. The function and activity of 
many proteins can be regulated by post-translational modification. The presence of NO 
can modify many proteins thereby regulating their function. NO can modify free thiols on 
cysteine residues in a process called S-nitrosation/nitrosylation237,238. As shown in the 
Figure 1.12, proteins can undergo S-nitrosation or S-nitrosylation as well as be 
denitrosylated, or removal of the NO group on the thiol239. Glutathione and thioredoxin 
systems are necessary for these processes. S-nitrosoglutathione (GSNO) reductase 
(GSNOR) denitrosylates proteins240,241. GSNOR may potentially play a role in regulating 
blood pressure. Inhibitors of GSNOR cause vasodilation and deletion of GSNOR causes 
an overall decrease in vascular resistance242-244. Although S-nitrosation occurs in normal 
physiological conditions, excessive oxidative or nitrosative stress can cause s-nitrosation 
of sGC. For example, treatment with nitroglycerin, in vivo, was shown to induce S-
nitrosation of sGC245. This can decrease activity of sGC and desensitize sGC to 
surrounding NO. S-nitrosation of sGC can serve as a negative feedback loop and 
therefore decrease cGMP production246. On the other hand studies have shown that S-
nitrosation may occur on cGMP phosphodiesterases, enzymes that degrade cGMP, and 





Figure 1.12: The roles of cGMP and S-nitrosylation in NO-based signaling (A) and enzymatic protein 
denitrosylation mediated by the S-nitrosoglutathione reductase (GSNOR) and thioredoxin (Trx) systems 
(B). (A) NO synthase (NOS) synthesizes NO, which may activate soluble guanylyl cyclase and thereby 
enhance production of cGMP (left) or subserve protein S-nitrosylation (right). The cGMP-dependent 
pathway is deactivated by cGMP-phosphodiesterase (PDE), which hydrolyzes cGMP to GMP (PDE may 
also be activated allosterically by cGMP). The SNO-based mechanisms are dynamically regulated via S-
nitrosylation and denitrosylation of a multitude of cysteine-containing proteins. In contrast to the multiple 
elements regulated by S-nitrosylation, the cGMP-based signaling system relies primarily on the cGMP-
dependent protein kinase, PKG. (B) Proteins undergo reversible S-nitrosylation and denitrosylation 
(center). Denitrosylation mediated by GSNOR is depicted on the left. Transnitrosylation of glutathione 
(GSH) by S-nitrosylated proteins generates GSNO and native protein. GSNO undergoes NADH-dependent 
reduction by GSNOR to generate glutathione S-hydroxysulfenamide (GSNHOH), which can undergo 
further reaction with GSH to generate oxidized glutathione (GSSG). The redox cycle is completed by 
reduction of GSSG to GSH via GSSG reductase. Denitrosylation mediated by the thioredoxin (Trx) system 
is depicted on the right. The active site dithiol motif (CXXC) of Trx1 (cytoplasmic) or Trx2 
(mitochondrial) undergoes oxidation coupled to denitrosylation of SNO substrate. Oxidized Trx is reduced 
by the selenoprotein thioredoxin reductase (TrxR), which employs the reducing power of NADPH to 
regenerate active Trx. From: Lima, B., Forrester, M. T., Hess, D. T. & Stamler, J. S. S-nitrosylation in 










sGC and the Heart 
 
Dysfunction in the eNOS/sGC/PKG pathway has been discovered and investigated as the 
cause in many diseases such as acute heart failure (HF), DN, ischemic diseases, 5/6 
nephrectomy, anti-thy1 glomerulonephritis and others247-249. The amount of NO in the 
microenvironment of these diseases has pushed investigators to design and investigate 
compounds that can efficiently target sGC and maintain cGMP production. In the case of 
HF, there is an increase in oxidative stress that can affect the redox state of sGC250. The 
increase in ROS creates a toxic environment in the endothelium by scavenging for 
surrounding NO and forming peroxynitrite (ONOO-)251. The resulting ONOO- 
production occurs at faster rate than the rate for GPx to neutralize ONOO- levels, leaving 
the endothelium damaged252. ONOO- can damage DNA and modify proteins inhibiting 
their function, as well as deplete GSH levels needed for GPx function252. Originally, NO 
donors such as nitroglycerin were administered to combat the decrease in NO 
bioavailability and hopefully still stimulate cGMP production and therefore 
vasorelaxation of blood vessels253. However, administering nitroglycerin increased 
ONOO- levels and decreased downstream PKG signaling subsequently decreasing 
vasorelaxation254.  
 
To target cGMP production in environment with low NO bioavailability, investigators 
discovered the first sGC modulator, YC-1255. YC-1 could increase cGMP production 
efficiently and was used as a lead compound for the design of other modulators256. There 
are two classes of sGC modulators, sGC stimulators and activators. sGC stimulators such 
as Riociguat, target the NO-sensitive/reduced state of sGC sensitizing sGC to endogenous 
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levels of NO that may still be produced in the toxic environment. sGC activators such as 
Cinaciguat, target two forms of sGC: the NO-independent/oxidized state of sGC and 
hemeless sGC.  The balance between reduced and oxidized sGC is complex and can shift 
towards oxidized sGC in these diseases. Excessive ROS in the endothelium can oxidize 
the heme moeity in sGC from its ferrous state to ferric and possibly remove the heme 
from the catalytic subunit completely250,257,258. The hemeless state of sGC can then be 
targeted for degradation259.  Several investigators have studied the role of both riociguat 
and cinaciguat in cardiovascular diseases260,261. As a result, currently riociguat is in 
clinical trials for pulmonary arterial hypertension (PAH) as ADEMPAS and cinaciguat 
for HF262,263. Both drugs have also shown to play a role in renal diseases such as CKD 

















Figure 1.13, shows a detailed diagram with cGMP and its three classes of targets. Both 
cGMP and cAMP compete for the allosteric binding sites on phosphodiesterases (PDEs). 
There are a total of 12 types of PDEs where certain PDEs such as PDE5, PDE6, and 
PDE9 have a higher affinity for cGMP than cAMP266. The lack of cGMP production in 
certain diseased states has raised the question for the role in PDE inhibition267. Sildenafil 
is a PDE5 inhibitor that has shown to play a role in recovery in renal I/R and to elicit 
















Figure 1.13: cGMP-PKG signaling pathway 
From: Kyoto Encyclopedia of Genes and Genome (KEGG)  04022 02/15/17, copyright from Kanehisa 









cGMP-Gated ion channels 
 
The second class of targets is cyclic nucleotide gated ion channels (CNGs). CNGs can by 
targeted by cGMP and cAMP, however their distributions varies and are commonly 
associated with sensory signal transduction. There are at least three classes of CNGs: 
CNG-1, CNG-2, and CNG-3. Although CNGs are primarily associated with 
photoreceptors and olfactory neurons, they are expressed in a wide variety of organs such 
as the brain, heart, colon, pancreas, lung, and kidney269. CNG-1 and CNG-3 expression 
exists in the kidney269. CNGs found in rod and cone channels are activated by cGMP 
whereas olfactory channels are activated by both cGMP and cAMP269. CNGs expressed 
in other organs play a role in regulating permeability to calcium and monovalent ions 
such as Na+ and K+.  
 
CNGs are non-selective ion channels that allow for the passage for both monovalent and 
divalent ions270. Their activity can be partly regulated by post-translational modifications 
such as phosphorylation and by the Ca2+ binding protein, calmodulin270,271. CNGs are not 
constitutively active and depend on the concentration of cGMP in the cell to stabilize a 
response270. CNGs in the kidney were found to contain characteristics in terms of 
activity, similar to CNGs in photoreceptors272,273. Upon further investigation, it was 
discovered that the cDNA for both types of CNGs share 99% nucleotide sequence 




Specific examples of CNGs in the kidney include epithelial sodium channels (ENaC) and 
Na+K+ATPase pumps274. ENaCs are responsible for Na+ reabsorption where upon 
binding cGMP can mediate effects of natriuresis, the excretion of sodium, and diuresis, 
the process of increasing urine volume182,275,276. Another CNG commonly expressed in 
the kidney as well as other organs is called Aquaporin-1 (AQP1), an osmotic water 
channel277. cGMP directly binds to the C-terminus of AQP1 and subsequently activating 
it and increasing water uptake277.  
 
Protein Kinase G 
 
The third class of cGMP targets is called protein kinase G (PKG), a 
serine/threonine kinase. There are two types of PKG: PKGI and PKGII. PKGI can be 
further characterized into two isoforms, PKG1a and PKG1b. Both isoforms are produced 
as a result of alternative splicing of the PKG1 (prkg1) gene and differ in the N-terminal 
amino acids278-281. Both isoforms exist in a variety of tissues however the proportion of 
expression of both, is cell type dependent281-283. PKG1a has a higher affinity for cGMP 
than PKG1b by 10 fold282,284,285. Many studies have suggested both isoforms sharing 
substrates however, this depends on the basal level of cGMP produced in the cell. If high 
amounts of cGMP are available in the cell and PKG1a is activated, PKG1b 
phosphotransferase activity can be activated as well. PKG1a will be the focus of this 
dissertation regarding PKG266.  
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PKG1 consists of a catalytic domain and a regulatory domain. The catalytic domain of 
PKG contains a subdomain that binds to Mg2+ and ATP as well as another subdomain that 
binds to substrates. cGMP binds to two allosteric sites in the regulatory domain and 
increases catalytic activity of PKG from 3 to 10-fold280,281,284,286,287. The regulatory 
domain contains an autoinhibitory domain and an extended leucine zipper region 
(ZZZZZ).  In the autoinhibitory subdomain, catalytic residues directly bind to residues in 
the autoinhibitory domain, suppressing catalytic activity in the absence of cGMP279,288. 
The autoinhibitory domain contains an amino acid sequence that is phosphorylated by the 
catalytic domain, although this residue cannot be phosphorylated266. This sequence, 
59TRQAIS63, is called a pseudosubstrate sequence, and the pseudo phosphorylation 
occurs on alanine266. Also in the catalytic domain, the leucine zipper region allows for 
dimerization of the PKG monomers and allows for specific targeting of certain proteins 
called cGMP-dependent protein kinase-interacting proteins (GKIPs)266. These 
interactions between PKG1 and GKIPs can help localize PKG to different parts of the 
cell and bind to its substrates266. Several examples of possible substrates of PKG1 include 
ATP-sensitive K+ channel289, MEKK1290, RhoA291-293, and Vasodilator-stimulated 
phosphoprotein (VASP)294,295. An updated list of potential substrates can be found in in-
depth reviews266,280.  
 
Although there are many substrates that are directly phosphorylated by PKG, there are 
several important proteins that can be considered as downstream targets that are 
associated with PKG. Much of the literature has shown a correlation between PKG and 
these associated downstream targets. These downstream targets include: AKT, ERK1/2, 
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Glycogen Synthase Kinase 3 β (GSK3β), and p38266,268,296-299. The following chapters 

























Mitochondrial homeostasis involves a network of cellular processes that regulate ATP 
production and the disruption of any of these processes can result in mitochondrial 
dysfunction and organ damage. Although much is known about mitophagy, fission, 
fusion, and MB, the precise role of these processes in renal disease remains to be 
determined. However, it is clear that mitochondrial dysfunction is common and occurs 
early in AKI and DN. Furthermore, the absence of recovery of mitochondrial function 
after diverse insults may lead to the continued impairment of renal function that leads to 
chronic renal disease. Because renal cell repair and the recovery of renal function is 
dependent on ability of mitochondria to produce ATP, restoring mitochondrial function 
might reverse cellular injury and restore renal function. Collectively, these studies 
corroborate the need to target mitochondrial homeostasis to reverse the state of disease, 
restore mitochondrial function and stimulate organ repair or prevent further decreases in 
organ function.  
 
Nisoli and group first suggested the role of NO in inducing mitochondrial biogenesis 
(MB)71. Moreover, this induction was also cGMP-dependent. Since this finding, there 
have been numerous studies in many different cell types regarding the cGMP-dependent 
pathway of inducing MB.  In the kidney specifically, although many correlations have 
been made between cGMP and MB, the pathway is still undefined. Here, we will 
elucidate how sGC/cGMP signaling regulates MB in the renal proximal tubule cells and 
in renal I/R.   
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Chapter Two: Characterization of Soluble Guanylyl Cyclase Signaling in the 
















































Soluble Guanylyl Cyclase (sGC) is the most common receptor for nitric oxide (NO) 
converting GTP to cyclic GMP (cGMP). sGC is a 150 kD heterodimer consisting of the 
alpha 1 and beta 1 subunits where the beta 1 subunit is the catalytic subunit and contains 
the heme moiety bound to Histidine 105234. The heme moiety predominantly exists in its 
reduced or ferrous form, Fe2+. Historically, sGC signaling begins with the generation of 
nitric oxide (NO) by one of three nitric oxide synthases (NOS): inducible, endothelial, 
and neuronal. The generation of NO by NOS occurs by oxidizing L-arginine to L-
citrulline300. NO binds to the heme moiety, inducing a conformational change in the 
enzyme and creating a pentacoordinated Fe-NO complex235. This conformational change 
induces a break between Histidine 105 and the bound heme moiety, subsequently 
activating the enzyme for the conversion of GTP to cGMP236. Although picomolar 
amounts of NO can activate sGC, in the presence of excessive NO sGC activity can 
increase by 100-fold301. The resulting production of cGMP can activate cGMP-gated ion 
channels, phosphodiesterases (PDEs), and protein kinase G (PKG). Commonly discussed 
effects of sGC signaling include vasodilation, vascular smooth muscle relaxation, and 
platelet aggregation, and potentially regulating mitochondrial biogenesis (MB)71.  
 
Conditions such as oxidative stress can negatively affect sGC signaling by introducing 
reactive oxygen species (ROS) that can scavenge for NO causing decreased downstream 
signaling. Conditions of excessive ROS can cause the oxidation of the ferrous heme in 
sGC, to ferric (Fe3+), allowing for inefficient production of cGMP. If conditions of 
excessive ROS persist, sGC can lose the heme moiety from its catalytic site creating the 
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heme-free state and rendering sGC completely inactive and vulnerable to degradation281. 
ROS can also target eNOS by inhibiting their function and decreasing overall NO 
bioavailability302,303. As a result, two classes of drugs were designed to 
pharmacologically target the reduced form of sGC or heme-dependent state and the 
oxidized form or heme-independent state. sGC stimulators, such as riociguat, target the 
reduced state of sGC by further sensitizing sGC and synergistically acting with 
endogenous NO to increase sGC activity304. sGC activators, such as cinaciguat, bind to 
the heme pocket and provide an additive effect to NO by replicating the NO-heme 
complex needed for activation259. Decreased NO bioavailability and perturbed sGC 
signaling has been discovered in many diseases such as cardiovascular disease, heart 
failure, ischemia and reperfusion injury (I/R), stroke, and pulmonary and systemic 
hypertension261,305-308.  In the kidney specifically, a role for sGC signaling has been 
suggested and shown in models of chronic kidney disease, anti-thy1 glomerulonephritis, 
5/6 nephrectomy, type-1 and type-2 diabetes, and I/R-induced AKI.  
 
Many studies, have shown and supported the role for mitochondrial dysfunction in the 
pathogenesis of I/R-induced AKI61,133,154,309,310. Moreover, some studies have suggested 
that cGMP can regulate MB71,72,311. There are two ways of directly sustaining cGMP 
production. The first is to activate sGC and the second is to inhibit the degradation of 
cGMP by targeting PDEs. PDE5, PDE6, and PDE9 have a higher affinity for targeting 
cGMP than cAMP for degradation266. We have previously shown in vivo, that targeting 
cGMP production by administering a PDE5 inhibitor, Sildenafil, attenuated renal 
dysfunction and the decrease in MB73. However, the role of sGC in regulating MB after 
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I/R is still under investigation. Here we characterize sGC signaling in the early phase of 
I/R in vivo by focusing on the first 24 hours of injury, the peak of maximal renal 






















Material and Methods 
Naïve mice studies 
Mice were sacrificed at 8 weeks of age and tissues were harvested and immediately flash 
frozen. 
 
Ischemia-reperfusion (I/R)-induced AKI mouse model 
Mice were subjected to bilateral ischemia where both renal pedicles were clamped for 18 
min at 37°C and then removed to reintroduce blood flow as previously described.155 
Sham mice were operated on in the same manner except for no clamping. Mice were 
sacrificed 24 h after injury and blood was collected via retro-orbital bleed. All tissues 
were flash frozen immediately.  
 
In vivo sGC activity 
When sacrificing mice, approximately half of the renal cortex is immediately isolated and 
put in 1mL of ice cold PBS and vortexed for 1 minute. The cold PBS is removed and the 
tissue is submerged in 500uL of lysis buffer including 50mM Tris-HCl, 1mM EDTA, 
1mM dithiothrietol and 2 mM phenylmethyl sulphonyl fluoride (PMSF) at pH 7.6. Tissue 
was homogenized using a dounce homogenizer and the mixture was centrifuged at 
20,000g for 20 min at 4C. Supernatants were collected and protein was measured. 
Reaction was prepared as previously described.250 Briefly, 50ug of protein was incubated 
with 100uL of reaction mixture containing 50mM Tris-HCl at pH:7.5, 7.5mM creatine 
phosphate, 0.2 mg/mL creatine phosphokinase, 1mM GTP,  4 mM MgCl2, 0.5 mM 
IBMX, and 1mM L-NAME with either 10uM riociguat, 10uM cinaciguat, 200nM mahma 
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nonoate at 37C. The reaction was terminated with the addition of 400uL of .05M of HCl.  
Products were flash frozen and stored at -80C until ready to measure cGMP by cGMP 
Elisa kit from Cayman Chemical.  
 
qRT-PCR 
RNA was isolated from renal cortical tissue using Trizol (Life Technologies). cDNA was 
produced using the iSCRIPT Advanced cDNA Synthesis Kit (Biorad) according to the 
manufacturer’s protocol. SsoAdvanced Universal SYBR Green Supermix reagent 
(BioRad) was used with the generated cDNA according to manufacturer’s protocol. 
mRNA expression was determined using a 2-triangle triangle CT method where mouse 
actin RNA was used for normalization.  
 
Immunoblot Analysis 
Half of frozen renal cortical tissue was isolated and put in RIPA buffer containing 50 mM 
Tris-HCl, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, pH 
7.4 with phosphatase inhibitors (1:100), 1mM sodium orthovanadate, and 1 mM sodium 
fluoride. Tissue was pulverized using a hand held homogenizer and sonicated for 
approximately 10 seconds. Tissue was centrifuged at 14,000 g for 15 min at 4C. 
Supernatants were removed and protein was measured using a BCA assay.  
 
Equal protein was loaded onto 4-15% SDS page gels and separated by gel 
electrophoresis. Protein was transferred onto nitrocellulose membranes and blocked in 
5% milk or 5% bovine serum albumin dissolved in TBST. Membranes were submerged 
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in primary antibodies overnight with rotation. The next day membranes were washed in 
TBST 3 times for 5 minutes each and were rotated in appropriate horseradish peroxidase–
conjugated secondary antibody. Membranes were visualized using enhanced 
chemiluminescence (Thermo Scientific) and the GE ImageQuant LAS4000 (GE Life 
Sciences). Optical density was determined using the ImageJ software from NIH.  
Measuring tissue cGMP 
Renal Cortical tissue was isolated from one whole kidney and cGMP was measured 

































sGC activity in naïve mice 
We sought to examine sGC activity in the kidneys of naïve mice.  We measured sGC 
activity in fresh renal cortex homogenates as previously described250 and determined 
linearity of the reaction in terms of homogenate protein content and reaction time. Frozen 
homogenates exhibited a marked reduction in sGC activity (data not shown). The NOS 
inhibitor L-NAME (1mM) was included in all to assays to prevent NO formation. cGMP 
formation was linear between 0.5 and 2 μg/μl and between 5 and 15 min (Fig. 2.1A).  
Using a homogenate protein concentration of 1 μg/μl and a 5 min reaction time, we added 
the NO donor, mahma nonoate (200nM) and observed a 3.4 fold increase in sGC activity 
compared to vehicle control (Figure 2.1B).  
 
To determine the effects of sGC activators and stimulators on sGC activity, we added 
riociguat (10 μM) or cinaciguat (10 μM), and observed 12-fold and 18-fold increases 
respectively (Figure 2.1B). We expected to see a robust increase in sGC activity with the 
addition of riociguat, because the reduced form of sGC predominates in naïve mice. 
Alternatively, cinaciguat targets only the oxidized/hemeless state of sGC, a small pool of 
oxidized sGC that exists in naïve mice312. Taken together, these results validate our assay 
for measuring sGC activity in the renal cortex and reveals marked increases in cGMP in 






Figure 2.1: sGC activity in naïve mice. Naïve mice at 8-10 weeks were sacrificed and 
renal cortical tissue was immediately isolated for determination of sGC activity. A) sGC 
activity determined in naïve mice on a protein and time dependent scale. B) sGC activity 
in naïve mice. Homogenates are dosed with 200nM mahma nonoate, 10uM riociguat, and 















sGC expression after I/R 
To confirm that mice subjected to I/R exhibited renal dysfunction at 24 h, serum 
creatinine was determined. Serum creatinine increased 11-fold to 1.8 mg/dL in I/R mice 
compared to Sham mice and renal cortical protein expression of kidney injury marker-1 
(KIM-1) and NGAL was observed in I/R mice (Figure 2.2A). 
 
To begin characterizing sGC signaling after I/R, we measured renal cortical protein and 
mRNA expression of the alpha 1 and beta 1 subunits 24 h after injury. There were no 
significant changes in protein expression of the alpha 1 and beta 1 subunits between sham 
and I/R mice (Figure 2.2C,E). Only mRNA expression for the alpha 1 subunit was 
















Figure 2.2: sGC expression after I/R A) Serum Creatinine of I/R mice compared to 
Sham in mg/dL. Representative blot of KIM-1 and NGAL. B and D) mRNA expression 
of Alpha 1 and Beta 1 subunits following I/R. C and E) densitometry analysis of alpha 1 
and beta 1 subunits following I/R. Data are represented as mean S.E., N=6-7. * represents 














NO-responsive/reduced sGC decreases after I/R 
We then detected sGC activity in the renal cortex 24h after I/R in the presence of 
riociguat and cinaciguat (Figure 2.3A). We found that basal sGC activity in I/R 
homogenates (I/R+LN) was significantly increased by 1.4 fold compared to Sham 
homogenates (Sham+LN). Responses to riociguat and cinaciguat were all significant 
compared to Sham+LN.  
We wanted to examine this data in a different manner to assess the individual 
changes between mice. sGC activity in Sham and I/R homogenates treated with riociguat 
and cinaciguat were normalized to their respective basal activities (Figure 2.3B). For 
example the value for I/R+cinaciguat was normalized back to the I/R+LN value for that 
mouse. sGC activity in Sham homogenates dosed with riociguat and cinaciguat were 
increased 18.3-fold and 21.1-fold compared to Sham+LN, respectively. However, sGC 
activity in I/R homogenates also dosed with riociguat and cinaciguat, showed a 9.5-fold 
and 17-fold increase compared to I/R+LN respectively. Using this approach, we observed 
a significant decrease in sGC activity in I/R+riociguat compared to Sham+riociguat. 
There was no difference between Sham+cinaciguat and I/R+cinaciguat groups. This 
indicates a decreased presence of the NO-responsive/reduced sGC after I/R. 
Although we have found an increase in sGC activity after I/R, we measured 
cGMP in the renal cortex of sham and I/R mice (Figure 2.3D). We observed a significant 
decrease in cGMP 24 h after I/R compared to Sham. The decrease in the reduced state of 
sGC is consistent with the decrease in renal cGMP. Oxidized sGC retains basal activity, 





Figure 2.3: NO-responsive/reduced sGC decreases after I/R A) sGC activity 24hr 
after I/R. B) Normalization of sGC activity to their respective L-NAME controls. * 
represents significance compared to Sham+riociguat C) Renal cortical cGMP 24h after 
I/R. Data are represented as mean S.E., N=6-12. * represents significance compared to 












PKG activation increases after I/R  
An increase in cGMP production can activate cGMP-gated ion channels, protein kinase G 
(PKG), and phosphodiesterases. At 24 h after I/R, PKG1α protein and mRNA were not 
affected (Figure 2.4C-D). Here we show that an increase in sGC activity activates PKG, 
24 h after I/R (Figure 2.4A-B). We determined the activation of PKG by measuring the 
phosphorylation of vasodilator-stimulated-phosphoprotein, VASP, a target of PKG295.  
We found an increase in the phosphorylation of VASP and in total VASP after I/R as 



















Figure 2.4: PKG activation increases after I/R A) Representative blot of PKG-1a, p-
VASP, Total VASP, and Actin showing Sham and I/R.  B) Densitometry analysis of p-
VASP. C) Densitometry analysis of PKG-1a. D) mRNA expression of PKG-1a following 
I/R. Data are represented as mean S.E., N=6-7. * represents significance compared to 














PKG-associated downstream targets increase after I/R 
Numerous studies have shown a trend between PKG activation and an increase in p38 
and/or ERK1/2 depending on the cell type299. We measured phosphorylation of p38 and 
found that it was increased by 2.2-fold in I/R compared to Sham mice (Figure 2.5A-B). 
We measured ERK1/2 phosphorylation and found a 3-fold increase in I/R compared to 
Sham (Figure 2.5A and C).  
 
Previous reports from this lab have elucidated the role of ERK1/2 phosphorylation in our 
model of I/R-induced AKI313,314. We reported that 3 h after I/R, ERK1/2 phosphorylation 
increases, subsequently increasing FOXO1 phosphorylation, a direct target of ERK1/2. 
Interestingly, phosphorylated p38 also targets FOXO1315. We measured FOXO1 
phosphorylation and found a significant decrease in p-FOXO1 at 24hr after I/R (Figure 















Figure 2.5: PKG-associated downstream targets increase after I/R A) Representative 
blot of p-ERK, Total ERK, p-P38, Total P38, pFOXO1, Total FOXO1, Actin. B) 
Densitometry analysis of p-P38 following I/R. C) Densitometry analysis of pERK 
following I/R. D) Densitometry analysis of p-FOXO1 following I/R. Data are represented 












MB is decreased 24 h after I/R 
We previously reported observing a decrease in MB 24 h after I/R. mRNA and protein 
expression of mitochondrial proteins such as NDUFB8, COX1, and ATP Synthase β 
were decreased after 24 h after I/R155. We confirmed the decrease in MB in our model by 
measuring PGC-1α. We found a significant decrease in mRNA expression (Figure 2.6a) 





















Figure 2.6: MB is decreased 24 h after I/R A) Representative blot of PGC-1α and 
Actin. B) Densitometry analysis of PGC-1α following I/R. C) mRNA expression of P 
PGC-1α. Data are represented as mean S.E., N=6-7. * represents significance compared 














The effect of Trametinib on sGC/cGMP/PKG pathway in I/R   
Based on our previous studies concerning the role of ERK1/2 in the early phase of I/R 
and as a potential mediator between PKG activation and decreased MB, we explored the 
effect of ERK1/2 inhibition on sGC signaling. To inhibit ERK1/2, we administered an 
inhibitor targeting a protein upstream of ERK1/2 called MEK1/2. Our previous studies 
show that administration of trametinib, a MEK1/2 inhibitor, effectively attenuated renal 
dysfunction by attenuating serum creatinine levels as well as MB at 3 h. We focused on 3 
h after injury, as events at this point play a major role in the resulting maximal 
dysfunction at 24 h. We measured the phosphorylation of eNOS and PKG activation at 3 
h with and without trametinib in Figure 2.7. We found a significant increase in 
phosphorylation of eNOS at ser1177 at 3 h after I/R and trametinib attenuated this 
increase (Figure 2.7A). At 3 h, phosphorylation of VASP is trending upwards and 

























Figure 2.7: The effect of Trametinib on sGC/cGMP/PKG pathway in I/R  A) 
Densitometry of p-eNOS following 3 h after I/R. B) Densitometry of p-VASP following 
3 h after I/R. Data are represented as mean S.E., N=3-4. * represents significance as 



























Previously in our laboratory, we have shown a persistent decline in mitochondrial 
function after I/R. PGC-1α, the master regulator of mitochondrial biogenesis (MB) is 
decreased 24 h after I/R as well as other mitochondrial proteins such as NDUFB8, ATP 
synthase B, and cytochrome c oxidase subunit 1 (COX1)155. Although we have identified 
several mechanisms that play a role in attenuating MB after I/R, the role of sGC is still 
under investigation.  
 
In naïve mice, sGC is predominantly in its reduced state, meaning the heme moiety is in 
its ferrous form. The ferrous form allows for proper binding of NO and subsequent 
cGMP production. To be able to measure the reduced form of sGC, we optimized an sGC 
enzyme assay from Thoonen et al, for the kidney250. After we showed linearity of our 
sGC assay at a protein and time dependent scale, in Figure 2.1b we show a robust 
response with mahma nonoate, the NO donor, and riociguat, the sGC stimulator that 
targets the reduced heme in sGC. The oxidation of the ferrous heme to ferric renders sGC 
less active unless treated with cinaciguat, the sGC activator that binds to the heme pocket 
sGC. However, oxidized sGC with no pharmacological administration still retains a 
certain level of basal sGC activity250,316. Studies have shown the presence of oxidized 
sGC in primary cultures of ovine fetal PASMCs (pulmonary arterial smooth muscle cells) 
by treating them with cinaciguat316. Thoonen et al, also showed the presence of sGC 
activity in apo-sGC mice compared to control mice250. The apo-sGC mice carry a H105F 
point mutation in the catalytic site of the beta 1 subunit, allowing for improper ligation of 
the heme moiety in the catalytic site. With this mutation, although the homogenates from 
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apo-sGC mice did not respond to an NO donor, these homogenates still had basal level 
sGC activity250. These studies support the existence for basal level activity of 
oxidized/heme-free sGC. Here in Figure 2.1b, we show a robust response in sGC activity 
when homogenates from naïve mice are dosed with cinaciguat. Our results are consistent 
with previous literature regarding the presence of oxidized sGC in naïve mice.   
 
In terms of I/R, other models of organ dysfunction such as cardiac I/R have shown that 
sGC can become oxidized and potentially heme free subjecting sGC for 
degradation257,317,318. In Figure 2.2, we found no change in the protein expression of the 
sGC subunits and therefore sought to measure sGC activity. In Figure 2.3, we show a 
decreasing presence of the reduced form of sGC after I/R, consistent with other models of 
I/R. The decrease in renal cortical tissue cGMP could be a result of the reduced form of 
sGC after I/R. The increase in basal sGC activity is not enough to be reflected at the 
tissue level, however seems sufficient enough to activate PKG, as shown in Figure 2.4. 
Although phosphorylation of VASP at ser239, a marker for cGMP specific activation of 
PKG, increases after I/R, interestingly we also found an increase in total VASP. This 
increase in total VASP could be due to the severity of renal injury, shown in Figure 2.2a. 
VASP is associated with regulating actin cytoskeleton and migration of certain types of 
cells, including renal cell types319,320. VASP is also associated with endothelial cell 
integrity in the kidney. Recent studies have also suggested an important role for VASP in 
renal injury321. VASP deficient mice subjected to I/R, show decreased long-term 
progression of nephrotoxic nephritis compared to wild type322. The increase in total 
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VASP can be a marker for injury and endothelial dysfunction therefore showing that the 
increase in PKG activation certainly plays a role in renal dysfunction after I/R321.  
 
The signaling pathway from increased PKG activation to decreased MB in I/R is still 
under investigation. p38 MAP Kinase and ERK1/2 MAP kinase are two regulators of 
PGC-1α in the kidney. Previous studies in our lab have elucidated the role for ERK1/2 in 
the regulation of MB after I/R313,314. We have also shown the importance of p38 in renal 
proximal tubular epithelial cell proliferation323. Both p38 and ERK1/2 also happen to be 
PKG-associated downstream targets. There is an abundance of literature regarding the 
correlation between PKG activation and downstream regulation of p38 and ERK1/2 in 
other models of I/R as well as the kidney266,268,299,324,325. We sought to explore the role of 
p38 and ERK1/2 as potential mediators between PKG activation and the down regulation 
of MB.   
 
We found an increase in the phosphorylation of p38 and ERK1/2 as shown in Figure 2.5. 
Previously we have shown that ERK1/2 can regulate PGC-1a transcription and 
subsequently MB, by phosphorylation of FOXO1, a transcription factor and a target of 
p38 as well315. Phosphorylation of ERK1/2 causes a phosphorylation of FOXO1, 
inhibiting the translocation of FOXO1 inside the nucleus. This causes a decrease in PGC-
1α mRNA and therefore MB. We sought to explore if ERK1/2/FOXO1 signaling was a 
mediator between PKG activation and PGC-1α mRNA. We measured the 
phosphorylation of FOXO1 and found that it was significantly decreased (Figure 2.5E). 
The phosphorylation of FOXO1 by ERK1/2 may not be necessary at 24 h since PGC-1α 
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protein and mRNA expression is decreased by this time point (Figure 2.6). These data 
show that ERK1/2 is not regulating MB through the phosphorylation of FOXO1 and this 
finding is unrelated to PKG activation.  
 
However, since the phosphorylation of FOXO1 may not be necessary for regulating 
PGC-1α transcription at 24 h, the role of ERK1/2 could still be a mediator between PKG 
activation and decreased MB. Therefore, we explored the effect of trametinib, a MEK 1/2 
inhibitor, on sGC signaling at 3 h in Figure 2.7. We focused on this time point because 
previous studies have shown that pretreatment with trametinib before I/R can attenuate 
serum creatinine within 3 h after I/R. Trametinib attenuated the increase in 
phosphorylated eNOS. The increase in phosphorylated eNOS could be producing nitric 
oxide that is toxic therefore sustaining injury. Trametinib did not attenuate the increase in 
PKG activation suggesting that trametinib may play a role in PKG activation independent 
of I/R.  
 
It is possible that p38 may play a role in suppressing MB however, we need to do further 
in vivo studies to elucidate the role and necessity of p38 after I/R. This study provides 
another perspective to the role of sGC in I/R. Further investigation is needed to determine 
if ERK1/2 is truly a mediator between PKG activation and decreased MB. Thus far, we 
have provided sufficient evidence hinting at ERK1/2 involvement in positively regulating 




Chapter Three: Elucidation of cGMP-dependent induction of Mitochondrial 
















































Soluble Guanylyl Cyclase (sGC) produces cGMP by converting GTP in the presence of 
nitric oxide (NO). cGMP can bind to cGMP gated ion channels, phosphodiesterases, and 
protein kinase G (PKG). cGMP plays a role in a variety of processes in the cell besides 
vasodilation, platelet aggregation, and smooth muscle vasorelaxation. Nisoli and group 
proposed that nitric oxide induces mitochondrial biogenesis through cGMP71,311. In our 
laboratory, we have shown mitochondrial respiration increase significantly in renal 
proximal tubule cells (RPTC) with 10μM b-Br-cGMP compared to cAMP suggesting that 
cGMP is responsible for inducing MB rather than cAMP73. Moreover, when RPTC are 
dosed with 8-Br-cGMP for 24 h, mRNA for several mitochondrial proteins increases as 
well as the master regulator of MB, PGC-1α increased73.  
 
Here, we have elucidated a pathway from cGMP to this increase in PGC-1α mRNA by 
focusing on events that may occur with in an hour of exposure to 8-Br-cGMP.  Several 
studies have supported the role for PKG involvement in mitochondrial function. PKG is a 
serine/threonine kinase and exists in two forms, PKG1 and PKG2. In renal tubular cells, 
PKG1 activity and expression decreased when exposed to cisplatin324. Increasing PKG1 
activity protected mitochondrial function, preventing cell apoptosis induced by 
cisplatin324. In an in vitro model for diabetes, adipocytes exposed to lipoamide were 
found to also induce MB through PKG providing a therapeutic target326. It was also 
shown in brown adipose tissue, that PKG mediates the effects of cGMP by inducing MB 
and increasing UCP-1327. Based on this literature, we chose to focus on PKG1, as the 
main target of cGMP, after exposing RPTC to 8-Br-cGMP.  
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Although there are many direct targets of PKG, including subunits of a variety of ion 
channels, there are few downstream associated targets such as ERK1/2, GSK3β, Akt, and 
p38328. The exact mechanism from PKG to these targets is unknown and still under 
investigation. We chose to focus on p38 for its role in regulating PGC-1α expression at 
the transcriptional and posttranslational level. Moreover, nitric oxide donors can induce 
p38 activation268,325,329. In brown adipose tissue, naturetic peptides activate Guanylyl 
Cyclase (GC) resulting in activated PKG330,331. Activated PKG leads to the 
phosphorylation of p38330. Phosphorylated p38 can phosphorylate PGC-1α increasing 






























Material and Methods 
In vitro Studies: 
Female New Zealand White rabbits (approximately 2Kg) were purchased from Charles 
River (Oakwood, MI/Canada). Renal Proximal tubule cells (RPTC) were isolated from 
kidneys using the iron oxide perfusion method. Cells were plated and grown on 35 mm 
tissue culture dishes in conditions that are similar to physiological conditions in vivo, as 
described previously332. The culture medium consisted of a 1:1 mixture of Dulbecco’s 
modified Eagle’s medium/F-12 (without glucose, phenol red, or sodium pyruvate) with 
15mM HEPES buffer, 2.5 mM L-glutamine, 1 uM pyridoxine HCl, 15 mM sodium 
bicarbonate, and 6 mM lactate. Hydrocortisone (50 nM), selenium (5 ng/ml), human 
transferrin (5 ug/ml), bovine insulin (10 nM), and L-ascorbic acid-2-phosphate (50 uM) 
were added to fresh culture medium. Only confluent RPTC were dosed with either 
compound or DMSO. The vehicle control for the inhibitor studies were dosed separately 
when dosing with inhibitors of PKG and p38.  
 
Subcellular Fractionation: 
Cells were harvested in 300uL of sucrose isolation (ISO) buffer containing 250 mM 
sucrose, 1 mM EGTA, 10 mM HEPES, and 1 mg/ml fatty acid free BSA at a pH of 7.4. 
Cells were homogenized using a dounce homogenizer and were then spun at 700 g for 5 
min. The supernatant is the cytosolic fraction was stored in another centrifuge tube with 
phosphatase inhibitors (1:100), 1mM sodium orthovanadate, and 1 mM sodium fluoride 
and concentrated Triton X-100 and SDS at 4%. The pellet was washed twice in ISO 
buffer and spun down at 1,000 g for 5 min each time. The pellet was then re-suspended in 
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200uL of RIPA buffer, phosphatase inhibitors (1:100), 1mM sodium orthovanadate, and 
1 mM sodium fluoride.  
 
Immunoblot Analysis 
RTPC were harvested in 200uL RIPA buffer containing 50 mM Tris-HCl, 150 mM NaCl, 
0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X-100, pH 7.4 with phosphatase 
inhibitors (1:100), 1mM sodium orthovanadate, and 1 mM sodium fluoride. Cells were 
sonicated for approximately 10 seconds. Cells were centrifuged at 7,500 g for 5 min at 
4C. Supernatants were removed and protein was measured using a BCA assay.  
Equal protein was loaded onto 4-15% SDS page gels and separated by gel 
electrophoresis. Protein was transferred onto nitrocellulose membranes and blocked in 
5% milk or 5% bovine serum albumin dissolved in TBST. Membranes were submerged 
in primary antibodies overnight with rotation. The next day membranes were washed in 
TBST 3 times for 5 minutes each and were rotated in appropriate horseradish peroxidase–
conjugated secondary antibody. Membranes were visualized using enhanced 
chemiluminescence (Thermo Scientific) and the GE ImageQuant LAS4000 (GE Life 
Sciences). Optical density was determined using the ImageJ software from NIH.  
 
qRT-PCR 
Cells were harvested in 400uL of Trizol (Life Technologies). cDNA was produced using 
the iSCRIPT Advanced cDNA Synthesis Kit (Biorad) according to the manufacturer’s 
protocol. SsoAdvanced Universal SYBR Green Supermix reagent (BioRad) was used 
with the generated cDNA according to manufacturer’s protocol. mRNA expression was 
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8-Br-cGMP activates PKG but does not affect PGC-1α protein expression 
To begin elucidating the pathway from cGMP production to PGC-1α expression, RTPC 
were treated with a cGMP analog, 8-Br-cGMP (10μM) for 1 h. Several studies have 
suggested that Protein Kinase G, PKG, could play a role in the regulation of 
mitochondrial biogenesis. Here we measured PKG activation by measuring the 
phosphorylation of vasodilator-stimulated phosphoprotein (VASP) at site serine 239 
(Figure 3.1A, 3.1C). We found a 1.9-fold increase in the phosphorylation of VASP 
compared to vehicle control (Figure 3.1C). We also treated RPTC with 10μM riociguat, 
an sGC stimulator that specifically targets the reduced in sGC. We found a 1.2-fold 
increase in the phosphorylation of VASP compared to control.  
 
We pretreated RPTC with 100nM KT5823 (KT), a PKG inhibitor, for 30 min and then 
treated with DMSO vehicle, 10μM 8-Br-cGMP, or 10μM riociguat for 1 h. These 
particular sets of experiments have their own vehicle control to take into account of 
additional DMSO due to pretreatment and to eliminate any effect caused by DMSO. 
Phosphorylation of VASP was decreased 30% in the KT+V treated group. In the 
KT+cGMP treated group, phosphorylation of VASP also decreased however, this 
decrease is not significant if compared to 8-Br-cGMP. KT did not affect the 
phosphorylation of VASP after the addition of riociguat.  At 1 h, we then measured PGC-
1α protein expression in all treatment groups (Figure 3.1B). We found no change in 
protein expression of RPTC dosed with 8-Br-cGMP, riociguat, KT+V, KT+cGMP, and 




Figure 3.1: 8-Br-cGMP activates PKG but does not affect PGC-1α protein 
expression A) Representative blot for PGC-1α, pVASP, and Tubulin after treatment. B) 
Densitometry analysis for PGC-1α protein. C) Densitometry analysis for pVASP protein. 













PGC-1α is phosphorylated and is located in the nucleus in the presence of 8-Br-
cGMP 
Since we detected no change in PGC-1α protein expression at 1 h, we sought to measure 
the phosphorylation of PGC-1α, an event that may be possible within 1 h of dosing. 
Moreover, we were interested in knowing the location of phosphorylated PGC-1α. 
Phosphorylation of PGC-1α at serine and threonine sites by p38 can increase the stability 
of PGC-1α and sustain transcription of PGC-1α62. We treated RPTC with 8-Br-cGMP, 
riociguat, and KT, similar to the dosing regimen in Figure 3.1. We first subjected RPTC 
to subcellular fractionation and tested for purity of nuclear and cytosolic fractions by 
measuring alpha tubulin, a cytosolic marker, and Lamin B, a nuclear marker (Figure 
3.2A). Secondly, we immunoprecipitated PGC-1α and blotted for phosphorylated serine 
and threonine residues in both the nuclear and cytosolic fractions (Figure 3.2B-C). We 
found a significant increase in phosphorylated PGC-1α in the nuclear fraction when 
dosed with 8-Br-cGMP by 1.64 fold (Figure 3.2D). We found that treatment with KT 
inhibited phosphorylation of PGC-1α in the nucleus. We did not find any significant 
changes in the phosphorylation of PGC-1α in the cytosolic fraction compared to vehicle 
control, although it seems phosphorylation of PGC-1α is trending upwards when RPTC 








Figure 3.2: PGC-1α is phosphorylated and is located in the nucleus in the presence 
of 8-Br-cGMP A) Representative blot of Tubulin and Lamin B showing purity of 
Cytosol and Nuclear fractions. B and C) phosphorylated serine and threonine residues 
were measured following immunoprecipitation of PGC-1α by immunoblot analysis after 
30 min treatment with DMSO or 100nM KT5823 followed by exposure to DMSO, 8-Br-
cGMP, and Riociguat in cytosol and nuclear fractions. Total PGC-1α expression was 
measured after immunoprecipitation. D and E) Densitometry analysis for phosphorylated 
serine and threonine residue in the cytosol and nuclear fractions. Data are represented as 











KT5823 inhibits p38 phosphorylation 
Due to our results in Figure 3.2, we hypothesized that p38 is the mediator between PKG 
activation and phosphorylation of PGC-1α. Many studies have suggested a role for p38 in 
the regulation of MB when NO donors are administered in vitro. Previously in this 
laboratory we have also shown that p38 is necessary for RPTC proliferation and that p38 
may play a role in recovery of RPTC when exposed to oxidant injury323,333. p38 can also 
phosphorylate PGC-1α at Threonine 298, Threonine 262, and Serine 265 as mentioned 
above and can increase the stability of PGC-1α in brown adipose tissue62. To elucidate 
this signaling, we measured p38 phosphorylation (p-p38) in the presence and absence of 
100nM KT (Figure 3.3). We that found that 8-Br-cGMP increased p-p38 by 1.5 fold. 
Riociguat also significantly increased p-p38. KT inhibited the phosphorylation of p38 









Figure 3.3: KT5823 inhibits P38 phosphorylation A) Representative blot for p-P38, 
p38 total, and Tubulin. B) Densitometry analysis for p-p38 protein. Data are represented 


















Inhibition of p38, inhibits PGC-1α phosphorylation at serine and threonine sites 
Although p38 is downstream of PKG activation based on our results, we sought to 
explore whether p38 is phosphorylating PGC-1α. We pretreated RPTC, similar to the 
KT5823 experiments, for 30 min with an inhibitor of p38, L-skepinone, at 100nM and 
then treated with vehicle, 10μM 8-Br-cGMP, and 10μM riociguat for 1 h and 2 h. We 
wanted to first validate inhibition of the phosphorylation of p38 at 1 h and at 2 h (Figure 
3.4A-B). We found that administration of 100nM of L-skepinone (LS) successfully 
inhibited the phosphorylation of p38 when dosed with 8-Br-cGMP and riociguat at both 1 
h and 2 h (Figure 3.4C-D).  We then measured phosphorylation of PGC-1α with L-
skepinone (Figure 3.4E-F). We found no significant change between L-Skepinone (LS) 
treated groups (LS+Vehicle, LS+cGMP, LS+riociguat) and vehicle. This indicates that L-









Figure 3.4: Inhibition of p38, inhibits PGC-1α phosphorylation at serine and 
threonine sites A and C) Representative blot for p-p38, p38 total, and tubulin after 
treatment with 30 min treatment with DMSO or 100nM L-Skepinone followed by 
exposure to DMSO, 8-Br-cGMP, and riociguat for 1 h and 2h. B and D) Densitometry 
analysis of p-p38 after 1h and 2h treatment respectively. E) Representative blot of 
phosphorylated serine and threonine residues following immunoprecipitation of PGC-1α 
by immunoblot analysis after 30 min treatment with DMSO or 100nM L-Skepinone 
followed by exposure to DMSO, 8-Br-cGMP, and riociguat in nuclear fractions. Total 
PGC-1α expression was measured after immunoprecipitation. F) Densitometry analysis 
for phosphorylated serine and threonine residue in the nuclear fractions. Data are 
represented as mean S.E., N=7-8 for A-D, N=4-5 for E-F. * represents significance 




PGC-1α mRNA increases at 4 h with 8-Br-cGMP 
Phosphorylation of PGC-1α at Threonine 298, Threonine 262, and Serine 265 by p38 can 
increase the half-life of PGC-1α and therefore increase transcription of PGC-1α as well62. 
We have previously shown an increase in PGC-1α transcription at 24 h with 8-Br-cGMP 
however, the mechanism behind this increase is unknown73. Based on our results, we 
found an increase in the phosphorylation of PGC-1α at 1 h with 8-Br-cGMP. We wanted 
to see if there would be a rise in PGC-1α mRNA after this phosphorylation event. We 
measured PGC-1α mRNA in RPTC dosed with vehicle, 10μM 8-Br-cGMP, and 10μM 














Figure 3.5: PGC-1a mRNA increases at 4 h with 8-Br-cGMP PGC-1α mRNA was 
measured after RTPC were dosed with DMSO, 10uM 8-Br-cGMP, and10uM Riociguat 
for 4 h. Data are represented as mean S.E., N=5 * represents significance compared to 

























Previous studies from our lab have shown that cGMP can induce MB in RPTC73. We 
dosed with 10μM 8-Br-cGMP for 24 h and found an increase in PGC-1α mRNA as well 
as the mRNA for other mitochondrial proteins73. However, the mechanisms for how 
cGMP can induce MB is unknown and still under investigation for different cell types. 
Here we have elucidated the pathway between cGMP and PGC-1α in renal proximal 
tubule cells (RPTC).  
 
We treated RPTC for 1 h with DMSO, 10μM 8-Br-cGMP and 10μM riociguat, an sGC 
stimulator that targets the reduced/heme-dependent form. The reduced form predominates 
in naïve cells and therefore, we included riociguat in all of our experiments for 
comparison. We measured PKG activation by measuring the phosphorylation of VASP 
(pVASP) at serine 239 and we measured PGC-1α protein in Figure 3.1. The increase in 
pVASP proved that our dosing of 8-Br-cGMP was effective since PKG is a direct target 
of cGMP. We expected to see no change in PGC-1α protein or mRNA (data not shown) 
since the dosing was only for an 1 h and this time point is too short. The half-life of PGC-
1α is approximately 31 min and therefore phosphorylation of PGC-1α is a possible event 
that may occur within an hour of dosing334. Phosphorylation of PGC-1α by p38 at 
specific sites such as Threonine 298, Threonine 262, Serine 265 increases the stability of 
PGC-1α335. In Figure 3.2, we show that PGC-1α is phosphorylated at serine and threonine 
residues and is located in the nucleus when RPTC are dosed with 8-Br-cGMP. Another 
important finding in Figure 3.2, is that KT5823, the PKG inhibitor, inhibits 
phosphorylation of PGC-1α. We hypothesized that activated p38 phosphorylates PGC-1α 
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at Threonine 298, Threonine 262, Serine 265 in the cytosol then translocates to the 
nucleus to sustain PGC-1α transcription. 
 
p38 is a downstream-associated target of PKG. Several studies have shown a correlation 
between both proteins329. Isolated cardiomyocytes dosed with sodium nitroprusside 
(SNP), an NO donor, activated p38 through a cGMP-dependent mechanism336. 
Lipopolysaccharide (LPS)-stimulated human neutrophils produced NO and cGMP 
leading to the activation of p38 through PKG337. Although other studies may suggest that 
p38 regulation by NO can be cGMP-independent, here we show that p38 phosphorylation 
is downstream of PKG and its activation is inhibited by KT5823 in Figure 3.3. Moreover, 
p38 inhibition also inhibited phosphorylation of PGC-1α at serine and threonine residues 
as we showed in Figure 3.4.  
 
The effect of riociguat on cGMP signaling in RPTC is not clear. We found a slight 
increase in pVASP, although not significant, in the presence of riociguat. Regulation of 
sGC activity or expression of its subunits in naïve RPTC are unknown and therefore it is 
possible that longer exposure to riociguat is required to see a robust effect of riociguat on 
this pathway. An hour treatment may have proved to be insufficient. Targeting sGC is 
upstream of cGMP production and therefore may prove to be more difficult to elucidate 
signaling since the amount of cGMP produced in the presence of riociguat may not be 
equivalent to the effect of 10μM 8-Br-cGMP.  
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Here we propose a pathway between cGMP and PGC-1α in RPTC mediated by PKG and 























Chapter 4: Conclusions and Future Directions to the Role of Soluble Guanylyl 

























Here we have presented a study discussing the role of sGC in regulating mitochondrial 
biogenesis (MB) in renal proximal tubule cells (RPTC) and in renal injury. We proposed 
opposing roles of sGC. In chapter two, we proposed that sGC plays a role in suppressing 
MB in the early phase of I/R. On the other hand, in chapter three, we elucidated a 
signaling pathway from cGMP production to PGC-1α transcription and translation in 
RPTC. 
 
In chapter two, we showed that sGC activity is slightly increased after I/R. However, the 
redox state of sGC is altered after injury. We utilized the pharmacological differences 
between riociguat and cinaciguat to target two different redox states of sGC. We 
discovered that after I/R, the reduced form of sGC decreases. Interestingly, renal cortical 
tissue cGMP also decreased and this finding is consistent with the decreased presence of 
the reduced state of sGC. If the heme moiety in sGC is oxidized cGMP production will 
be compromised. However, PKG was activated 24 h after I/R suggesting that cGMP 
production after I/R was sufficient enough, even though these levels are decreased at the 
tissue level. One plausible explanation of this increase in sGC activity after I/R, can be 
found at 3 h after I/R. At 3 h after I/R, Akt phosphorylation is increased. Endothelial 
NOS is a target of Akt if phosphorylated at serine 1177 and is increased at 3 h after 
I/R338. The reactive oxygen species introduced with I/R injury as well as the increased 
production of NO can increase sGC activity after I/R.  
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After discovering that PKG is activated I/R, we explored potential downstream targets of 
PKG such as ERK1/2 and p38, both of which were increased after I/R. Phosphorylation 
of FOXO1, the downstream target of ERK1/2, decreased at 24 h after I/R suggesting that 
ERK1/2 is not regulating FOXO1 at this time point. This data also showed that the 
resulting FOXO1 signaling is independent of PKG.  
 
It is not certain, whether ERK1/2 or p38 is the mediator between PKG activation and 
decreased MB. To explore the role of protein in this process, we utilized trametinib, a 
MEK1/2 inhibitor that successfully inhibits the phosphorylation of ERK1/2. Surprisingly, 
we discovered that pretreatment with trametinib attenuated the phosphorylation of eNOS 
at 3 h after I/R. Moreover, PKG activation seemed to be trending upwards at 3 h after I/R 
and trametinib had no effect. However, knowing that ERK1/2 inhibition attenuates renal 
injury, this ERK1/2 induced PKG activation may have a renoprotective effect. Although 
this piece of data may hint at ERK1/2 involvement in sGC suppression of MB, further 
investigation is necessary. 
 
In chapter three, in our in vitro studies we show that 8-Br-cGMP, a cGMP analog, 
activates PKG. We verified this activation by measuring the phosphorylation of VASP, 
vasodilator stimulated phosphoprotein. Moreover, we show that there is also an increase 
in p38 MAPK activation. If PKG activation is inhibited, p38 activation is also inhibited. 
This finding shows that p38 is a downstream target of PKG, although is not directly 
phosphorylated by PKG. Further studies are needed to elucidate this PKG/p38 
connection. Interestingly, p38 can directly phosphorylate PGC-1α on Threonine 262, 
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Threonine 298, and Serine 265 therefore increasing the half-life of PGC-1α and 
increasing its transcription62. We show an increase in the phosphorylation of PGC-1α at 
serine and threonine sites in the presence of 8-Br-cGMP. Surprisingly, inhibiting PKG 
also inhibited the phosphorylation of PGC-1α. Finally, to prove that p38 is the mediator 
between PKG and the phosphorylation of PGC-1α, we used a p38 inhibitor, L-Skepinone. 
Pre-treatment with L-Skepinone attenuated the increase in the phosphorylation status of 
PGC-1α proving that p38 is indeed the mediator.  
 
These findings are novel in that this particular mechanism exists in RPTC. These 
experiments included riociguat, an sGC stimulator. Although riociguat slightly increased 
phosphorylation of VASP and increased p38 activation at 1 h, it is not certain whether 
riociguat increased the phosphorylation of PGC-1α. It is possible that this event may not 
occur within an hour of exposure. Here in chapter two, we show a positive role for sGC 




Although in both chapters we have provided proof for a role for sGC in regulating MB, 
there are several unanswered questions that should be addressed to better elucidate sGC 
signaling in RPTC and in renal injury.  
 
In terms of renal injury, the first question regards the importance of sGC in renal injury. 
The function and activity of sGC is a complex process and depends on the 
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microenvironment of the enzyme. Different types of insults can trigger different signaling 
pathways that begin with the activation of sGC. To answer this question, apo-sGC mice 
can be useful in elucidating sGC signaling. Apo-sGC mice contain a point mutation in the 
beta 1 subunit, the catalytic subunit of sGC, where the heme moiety is attached to the 
amino acid, phenylalanine instead of histidine250. This allows for improper ligation of 
heme moiety. As discussed in detail in chapter two, sGC activity in apo-sGC mice is 
decreased in the presence of nitric oxide donors250. It would be worthwhile to measure 
PGC-1α mRNA and protein as well as mitochondrial DNA copy number. Other 
mitochondrial proteins should be measured as well. If sGC plays a vital role in regulating 
MB, our hypothesis is that MB would be decreased in these mice. Secondly, to determine 
if sGC is absolutely necessary in the recovery or prevention of renal injury, apo-sGC 
mice should undergo I/R. It is possible that these mice may not even survive the surgery 
since cGMP production is dysfunctional and cGMP is necessary for vasodilation. 
However, if the apo-sGC mice do survive the surgery, markers of MB should be 
measured.   
 
The second unanswered question revolves around sGC function and activity. Post-
translational modifications of sGC include S-nitrosation and phosphorylation although, 
phosphorylation is an event that occurs rarely and is still under investigation. S-
nitrosation of sGC can occur under conditions of oxidative and nitrosative stress. In 
conditions of I/R, S-nitrosation of sGC can decrease cGMP production245,339. Measuring 
S-nitrosation of sGC, although difficult, would give more insight into the 
microenvironment of sGC after I/R.  
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sGC function can depend on the presence of other proteins such as Hsp90340. Hsp90 is a 
chaperone heat shock protein that is associated with sGC341,342. Hsp90 can assist with 
inserting the heme moiety in the catalytic subunit of sGC343. Successful heme insertion 
allows for proper ligation and stabilizes the sGC heterodimer344. Hsp90 dissociates from 
the mature dimer allowing for NO to bind340. In conditions of oxidative stress or when the 
heme is oxidized, Hsp90 will re-associate with the beta 1 subunit as shown in Figure 4.1. 
It would be interesting to investigate the role of Hsp90 after I/R and if it is bound to sGC. 
Based on our results thus far, we would hypothesize Hsp90 association to sGC since we 
detected a decrease in the reduced state of sGC after I/R. Exploring the role of Hsp90 














Figure 4.1: sGC NO response, maturation, and exclusive interaction of sGC-β1 with hsp90 versus 
sGC-α1. An equilibrium exists in cells between an hsp90-bound apo-sGC-β1 and a heme-replete sGC-β1 
that is associated with sGC-α1. NO can rapidly shift this equilibrium to the right when cell heme levels are 
sufficient and hsp90 is active. NO can then bind to the heme in the sGC heterodimer and activate catalysis 
(lower right). Further NO exposure may cause S-nitrosation of sGC-β1 and heme oxidation/loss and 
thereby desensitize sGC toward NO and promote its hsp90 reassociation. Binding of the heme-independent 
activator, BAY 60-2770 (blue), to the apo-sGC-hsp90 species can occur independent of active hsp90 and 
cellular heme, and this triggers the same changes in sGC-β1 structure and protein interactions that are 
needed to activate its catalysis. From: Ghosh, A. & Stuehr, D. J. Regulation of sGC via hsp90, Cellular 
Heme, sGC Agonists, and NO: New Pathways and Clinical Perspectives. Antioxid. Redox Signal. 26, 182-
















The final question that will be discussed here is the pathway between PKG and 
mitochondrial biogenesis. As mentioned above in chapter two, we provide evidence for 
possible ERK1/2 involvement. However, there is a possibility that other mediators can 
play a role in the pathway. First, we will address p38 as a potential mediator. To properly 
address this, we would administer a p38 inhibitor, SB203580, at two doses 10 mg/kg and 
3 mg/kg 1 h before I/R. It is not certain whether the increase in the phosphorylation of 
p38 is part of activating the inflammatory response therefore possibly playing a 
detrimental role or if it is necessary for the recovery from I/R. At either dose, SB203580 
should inhibit the phosphorylation observed 24 h after I/R. If p38 plays a role in 
regulating MB, then we hypothesize that either dose of SB203580 should attenuate renal 
injury and prevent the decrease in MB. It is well known that p38 can regulate the 
inflammatory response by triggering the transcription of pro-inflammatory cytokines 
such as IL-6, TNF-a, and IL-8345-347. It is possible that inhibiting p38 may primarily 
inhibit this inflammatory response and have no effect on MB.  
 
It is not clear how PKG may be involved in the phosphorylation of p38. Several studies 
have shown that PKG can directly phosphorylate MEKK1 in its N-terminal domain290. 
MEKK1 is an upstream target of MAPK proteins such as JNK and p38348. Although it’s 
mostly associated with the JNK pathway, crosstalk exists between both the JNK and p38 
pathways (Figure 4.2)349. MEKK1 can directly activate an upstream targets of p38349,350. 
It would be worthwhile to measure MEKK1 24 h after I/R, as well in the in vitro studies 
we discussed in chapter three. In the case of our in vitro studies, although we showed 
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inhibition of p38 by inhibiting PKG activation, measuring MEKK1 activation in these 




















Figure 4.2: Overview of mammalian mitogen-activated protein kinase (MAPK) signaling cascades 
From: Takekawa, M. & Kubota, Y. in Protein Modifications in Pathogenic Dysregulation of Signaling   












Although elucidating the role of MEKK1 may provide better insight especially in our in 
vitro studies, it does not address how phosphorylated p38 or ERK1/2 contribute to 
decreased MB at 24 h in our in vivo studies. Therefore, we thought about targets of PKG 
that play a role in maintaining mitochondria function. In the early phase of I/R, several 
groups have observed mitochondrial swelling and fragmentation and cell death169,351-354. 
There is an increase in calcium levels inside the mitochondria and ATP levels are 
decreased355,356. These events trigger the opening of the mitochondrial permeability 
transition pore (MPTP)356. In recent years, the role of a mitochondrial potassium channel 
(mitoKATP) that is located in the inner membrane, has gained attention in cardiac I/R. 
Ischemic preconditioning in the heart can open mitoKATP, releasing ROS from the 
mitochondria and reducing damage. Opening of these channels has shown to prevent the 
opening of MPTP, thereby providing a cardioprotective role for mitoKATP
357,358. PKG can 
target mitoKATP leading to a release in ROS and subsequent activation of ERK1/2 (Figure 
4.3)268,359,360. The interaction between PKG and mitoKATP is still under investigation. 
Some groups suggest that PKG transmits this cardioprotective signal to PKCe that is 
bound to the mitochondrial inner membrane361,362. PKCε is activated and directly 
phosphorylates mitoKATP causing it to open
361,363. This pathway was demonstrated in 
cardiomyocytes however, it is still unknown if this protective effect exists in renal I/R.  
 
Our previous studies regarding ERK1/2 in renal I/R prove that inhibiting ERK1/2 is 
renoprotective313,314. The mechanism described above in the case of cardiac I/R shows 
that phosphorylation of ERK is important to elicit cardioprotective effects. It seems that 
the importance of phosphorylated ERK1/2 is contradictory in terms of PKG-dependent 
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effects. Therefore, it would be beneficial to explore the role of PKG-dependent activation 
of mitoKATP and whether this compensatory mechanism is activated during I/R and if 
ERK1/2 does help elicit downstream effects. Taken together, the pathway from PKG to 
decreased MB needs further investigation as simultaneous events up until 24 h after I/R 




Figure 4.3: Proposed signaling pathways of PKG-dependent cardioprotection by sildenafil against 
myocardial ischemia-reperfusion injury. From: Das, A., Xi, L. & Kukreja, R. C. Protein kinase G-
dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK 




Appendix: M2 Phenotype Predominates in the Recovery Phase, 144 h after 

























In renal ischemia and reperfusion injury (I/R), events that take place from the early phase 
of I/R to the late phase are intricate and complex.  Within the first 24 h after I/R, there is 
an influx of reactive oxygen species (ROS) and a significant increase in the release of 
proinflammatory damage-assocated molecular patterns (DAMPs), hypoxia-inducible 
factors (HIFs) and adhesion molecules from the injured tubular epithelium364,365. Pro-
inflammatory cytokines and the release of these molecules facilitate the recruitment of 
many types of immune cells such as neutrophils, monocytes, dendritic cells, B cells, T 
cells, and NK cells365. A few studies have shown that preventing the influx of certain 
immune cells such as neutrophils can reduce the amount of renal damage and accelerates 
recovery366.  
 
Resident immune cells in the kidney such as macrophages increase in number after 
I/R367,368. The microenvironment created by proinflammatory cytokines, DAMPS, and 
HIFs activate resident macrophages as well as infiltrating monocytes to adopt a 
proinflammatory phenotype367. These proinflammatory macrophages produce NO, 
adding to the ROS already present and inflict further tubular injury. Studies have beeen 
conducted showing that although macrophage depletion in the early phase of injury may 
be beneficial, macrophage depletion in the recovery phase decreases renal repair369-373. 
These studies imply that macrophages have a wide variety of characteristics that adapt to 
the microenvironment from the early phase of I/R to the late recovery phase. 
Macrophages can be defined in terms of a M1/M2 phenotype, where M1 macrophages 
are proinflammatory and M2 macrophages exhibit anti-inflammatory properties as shown 
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in Figure A1.1. The characteristics defining the M1/M2 phenotype are not absolute, 
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Here we attempted to characterize the M1/M2 phenotype in our model of I/R. The M1 
phenotype generally releases iNOS, or inducible NOS, and are activated by IFN-y and/or 
LPS367. They secrete proinflammatory cytokines such IL-6, IL-12, and TNF-a. M2 
macrophages, alternatively, express mannose receptor (MR), arginase 1 (Arg1), and 
macrophage scavenger receptor-1 (Msr1)367,379. The driving force behind the M1 or M2 
phenotype is macrophage colony-stimulating factor (M-CSF/Csf1) and granulocyte 
macrophage colony-stimulating factor (GM-CSF/Csf2). It seems the both are necessary 
for macrophages to adopt an M2 phenotype380,381. Inhibition of Csf2 before I/R, 
suppresses tubular repair while Csf1 can inhibit tubular apoptosis and facilitate tubular 
repair381,382.  
 
In this study we measured Csf1, Csf2, MR, Msr1 and Arg1 in our model of I/R. We 





















Material and Methods 
 
Ischemia-reperfusion (I/R)-induced AKI mouse model 
Mice were subjected to bilateral ischemia where both renal pedicles were clamped for 18 
min at 37°C and then removed to reintroduce blood flow as previously described.155 
Sham mice were operated on in the same manner except for no clamping. Mice were 
sacrificed either 24 h or 144 h after injury depending on the experiment and blood was 
collected via retro-orbital bleed. All tissues were flash frozen immediately.  
 
For LY344864 administration, mice were injected with 2 mg/kg intraperitoneally once 
daily, starting 24 h after I/R. Mice were sacrificed 144 h after I/R. All tissues were flash 
frozen immediately.  
 
Serum Creatinine Measurement 
Blood was collected via retro-orbital bleed. Blood was spun down at 10,000xg at 10 min. 
The supernatant was collected and immediately stored in the -80C. Serum creatinine was 
measured using the Diazyme kits per manufacturer’s protocol.  
 
qRT-PCR 
RNA was isolated from renal cortical tissue using Trizol (Life Technologies). cDNA was 
produced using the iSCRIPT Advanced cDNA Synthesis Kit (Biorad) according to the 
manufacturer’s protocol. SsoAdvanced Universal SYBR Green Supermix reagent 
(BioRad) was used with the generated cDNA according to manufacturer’s protocol. 
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mRNA expression was determined using a 2-triangle triangle CT method where mouse 

























Csf1, Csf2, Msr1, MR, and Arg1 mRNA expression is increased 144 h after I/R 
We measured mRNA expression of all markers at 24 h after I/R. We found a significant 
increase in Csf1 mRNA expression in the renal cortex at 24 h (Figure A1.2a). However 
mRNA expression of the other markers such as Csf2, Msr1, and MR did not increase at 
24 h after I/R (Figure A1.2b-e). Arginase 1 mRNA expression decreased after I/R 
although this comparison to sham mice was not significant (Figure A1.2d).  
 
In the midsection (total) of the kidney, we found no change in the mRNA expression of 
Csf2, Msr1, Arg1, and MR 24 h after I/R (Figure A1.2b-e). However, we found a 
significant increase in Csf1 mRNA expression 24 h after I/R (Figure A1.2a).  
 
We measured all five markers at 144 h after I/R and found a significant increase in the 











Figure A1.2: Csf1, Csf2, Msr1, MR, and Arg1 mRNA expression is increased 144 h after I/R mRNA 
expression of Csf1, Csf2, Msr1, MR, and Arg1 subunits following 24 and 144 h I/R. Data are represented 
as mean S.E., N=6-11. b represents significance compared to Sham, c represents significance compared to 
both sham and 24 h after I/R (p<0.05) 
 127 
Csf1 mRNA expression positively correlated with delta serum Creatinine and serum 
creatinine at 144 h after I/R 
We sought to investigate if a correlation existed between Csf1 mRNA expression and 
serum creatinine after I/R. We found two correlations significant for Csf1 mRNA 
expression. First, we measured serum creatinine at 144 h after I/R injury in all mice, 
including sham mice. We found a positive correlation in that as serum creatinine at this 
time point was attenuated near sham levels, Csf1 mRNA expression increased in both the 
renal cortex and in the total kidney shown in Figure A1.3a. Secondly, we measured delta 
serum creatinine for each animal subtracting serum creatinine measured at 144 h from 
serum creatinine measured at 24 h after I/R. The increase in delta serum creatinine 
indicates recovery from I/R. We found that as delta serum creatinine increased, so did 
Csf1 mRNA expression in both the renal cortex and in the total kidney as shown in 












Figure A1.3: Csf1 mRNA expression positively correlated with delta serum 
Creatinine and serum creatinine at 144 h after I/R mRNA expression of Csf1 at 144 h 
I/R in the renal cortex and total kidney correlated with serum creatinine at 144hr and 









As delta serum creatinine increased, so the did the mRNA expression for Arg1, MR, 
Msr1, and Csf2 
Similar to Figure A1.4, we made two correlations between serum creatinine and mRNA 
expression of all markers as shown in Figure A1.3. As serum creatinine at 144 h after 
injury decreased, mRNA expression for MR, Msr1, and Csf2 increased. Secondly, as 
















Figure A1.4: As delta serum creatinine increased, so the did the mRNA expression for Arg1, MR, 
Msr1, and Csf2 mRNA expression of Arg1, MR, Msr1, and Csf2 at 144 h I/R in the renal cortex and total 
kidney correlated with serum creatinine at 144hr and delta serum creatinine. Significance is represented 
with a R2 value.  
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LY344864 decreases Arginase 1 mRNA expression 144 h after I/R 
Previously in our lab, we have shown accelerated renal recovery in our model of I/R, 
after administration of LY344864, once daily starting at 24 h after I/R, for 144 h. We also 
showed recovery of mitochondrial biogenesis. Therefore, we were curious to see the 
effect of LY344864, a 5-HT1F agonist, on the mRNA expression of these markers. 
LY344864 had no effect on the mRNA expression of all of the markers except arginase 1. 
We found a significant decrease in arginase 1 after treatment with LY344864 at 144 h 


















Figure A1.5: LY344864 decreases Arginase 1 mRNA expression 144 h after I/R 
mRNA expression of Arg1 at 24 and 144 h I/R in the renal cortex and total kidney.  
mRNA expression of Arg1 at 144 h with LY344864 treatment.  Data are represented as 
mean S.E., N=6-11. b represents significance compared to Sham, c represents 































In this study, we wanted to characterize the M1/M2 phenotype in our model of I/R. We 
focused on the early phase of injury, which is 24 h after I/R and is also the peak of 
maximal renal dysfunction. We also focused on the recovery phase of I/R, which in our 
model occurs at 144 h after I/R.  
 
We found a significant increase in all markers at 144 h after injury in the renal cortex and 
in the total kidney (Figure A1.2). These increases are consistent with other studies that 
have shown that expression of arginase 1 and mannose receptor by M2 macrophages 
predominate in the recovery phase and their expression should be decreased in the early 
phase of injury. We compared the serum creatinine at 144 h as well as the delta serum 
creatinine with the mRNA expression of all these markers (Figure A1.3 and A1.4). Our 
results are consistent with other studies in that the recovery of each animal, as determine 
by increased delta serum creatinine, is associated with an increase in all five of these 
markers.  
 
Interestingly, Csf1 expression is increased in the renal cortex at 24 h after I/R although 
not significant. At 144 h after I/R, Csf1 mRNA expression is further increased in the 
renal cortex and in the total kidney. Csf1 is a cytokine that mediates crosstalk between 
macrophages and tubular cells383,384. Although further investigation is needed to elucidate 
this signaling, our data support theories regarding positive crosstalk between 
macrophages and tubular cells for renal repair384. The role of Csf2 is still unclear 
however, it is known that its expression is necessary for renal repair after I/R.  
 134 
Previously in our lab, we have shown the attenuation of renal function and recovery of 
mitochondrial biogenesis, MB, with the treatment of LY344864, a 5-HT1F agonist
180. In 
Figure A1.5, we were curious to see the effect of LY344864 on our markers. Except for 
Arginase 1, LY344864 did not have any effect on our other markers (data not shown). 
The decrease in arginase 1 mRNA expression due to LY344864 treatment is surprising. 
In cardiac I/R the prolonged presence of arginase 1 is not favorable for recovery385. Since 
we have shown previously that LY344864 attenuates renal function compared to sham 
mice, it is possible that one of the effects of LY344864 is decreasing arginase 1, 
providing a new insight into the importance of arginase 1 in the recovery phase of renal 
I/R. The mechanism behind LY344864 induced MB was elucidated in renal proximal 
tubule cells where the involvement of endothelial NOS was important386. A balance 
exists between eNOS expression and arginase 1 expression where both enzymes use L-
arginine to function. Moving forward, it would be worthwhile to investigate this balance 
between eNOS and arginase 1 expression in the presence of LY344864 144 h after I/R.   
Here, we have provided consistent evidence for the M2 phenotype 144 h after I/R in the 
recovery phase and have introduced an interesting effect of LY344864, that still needs to 
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